Document:

EX-10.17

 Exhibit 10.17 
 [Execution Copy] 
 TUFTS UNIVERSITY LICENSE AGREEMENT 

This Agreement is made and entered into as of February 1, 1997 (“the Effective Date”), by and between Paratek
Pharmaceuticals, Inc., a Delaware corporation having an address of P.O. Box 1525, Boston, Massachusetts 02117-1525 (“Licensee”) and Tufts University, a/k/a Trustees of Tufts College, a corporation duly organized and existing under the laws
of the Commonwealth of Massachusetts and having a principal office at Medford, Massachusetts 02155 (“Tufts”). 

WHEREAS, Tufts possesses certain know-how, inventions and intellectual property in the field of drug resistance; 

WHEREAS, Tufts, acting through Dr. Stuart Levy, (the “Principal Investigator”) wishes to and is prepared to conduct
additional research in this field under a Sponsored Research Agreement of even date herewith; 
 WHEREAS, Licensee is prepared
to provide support to Tufts for such research by the Principal Investigator, providing it receives certain license rights under inventions, biological materials, and/or know-how developed in the research under
the terms of this License Agreement; and 
 WHEREAS, Tufts wishes to have such inventions, biological materials, and/or know-how perfected and marketed in order that products resulting therefrom might be available for public use and benefit. 
 NOW THEREFORE, for valuable consideration, the receipt and adequacy of which are hereby acknowledged, and intending to be legally bound, the parties hereto mutually agree as follows: 

ARTICLE I - DEFINITIONS. 
 1.1. “Patent Rights” shall mean rights owned or controlled by Tufts which arise under United States or foreign patents or patent applications as described in Exhibit A or any patents issuing
from said applications that cover inventions which were discovered or developed at Tufts by Dr. Stuart Levy, alone or in conjunction with others, or which are discovered or developed in the Field of Use pursuant to the Sponsored Research
Agreement of even date herewith (the “Research Agreement”), including any divisions, continuations, continuations-in-part,
re-examinations, extensions, renewals, or reissues thereof. 
 1.2.
“Technology” shall mean the trade secret, know-how, and other proprietary, non-public information relating to the “Field of Use” and necessary or useful for practicing the Patent Rights
that was discovered or developed at Tufts by Dr. Stuart Levy, alone or in 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 
conjunction with others, or is discovered or developed pursuant to the Research Agreement and that has been revealed to Licensee pursuant to the Research Agreement or that may hereafter be
revealed to Licensee pursuant to the requirements of this Agreement or the Research Agreement. The Technology shall not include the Patent Rights but shall include any non-public information included in patent
applications if and when it is subsequently deleted therefrom before the patent is issued. 
 1.3. “Confidential
Technology” shall mean all Technology, and all information in or concerning patent applications included in the Patents, provided, however, that Licensee need not keep confidential any information that: 

(a) at the date of its disclosure by Tufts to Licensee was known to Licensee as documented in Licensee’s files and is revealed to
Tufts within thirty (30) days after Tufts’ disclosure to Licensee; or 
 (b) at the date of disclosure by Tufts to
Licensee was, or thereafter becomes, through no fault of Licensee, publicly known through publication or so widely known and used that it can be said to be generally available to the public. 

1.4. “Field of Use” shall mean the prophylaxis, treatment or prevention of bacterial or microbial diseases or medical
conditions in humans or animals or agriculture using (i) tetracycline derivatives or other compounds which affect tetracycline resistance or (ii) compounds based on knowledge of the MAR operon or (iii) compounds involving novel genes
which affect antibiotic resistance or microbial infectivity and which are derived from studies of the MAR operon or (iv) compounds that affect any such genes. 
 1.5. “License Period” shall mean collectively the respective periods commencing on the Effective Date and ending (unless sooner terminated) upon the later of the expiration of the last to expire
of the Patent Rights (treating pending applications as issued patents for so long as they are pending) and fifteen (15) years from the Effective Date. 
 1.6. “Licensed Products” shall mean all products that are within or made by a process within the Field of Use and that embody or are made in accordance with or using or are based upon or derived
from any aspect of the Patent Rights or the Technology. 
 1.7 “Gross Sales” shall mean the gross sales of Licensed
Products subject to royalty under this Agreement billed to customers by Licensee and its Subsidiaries, less the following: 

(a) [***]; 

(b) [***]; and 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 2 

 (c) [***]. 
 Gross Sales shall also include and be deemed to have been made with respect to any Licensed Products used by Licensee or any Subsidiary, for its own commercial purposes, or transferred to any third-party
for less than the transferee is then charging in normal arms-length sales transactions; and Gross Sales in all such cases shall be deemed to have been made at the prices therefor at which such Licensed Products are then being sold to the customers
of such user or transferor (or of Licensee, if a Subsidiary is a user but not a seller) in arms-length sales transactions. 
 In
the event that a Licensed Product under this Agreement is sold in combination with another active ingredient or component having independent therapeutic effect or diagnostic utility, then “Gross Sales,” for purposes of determining royalty
payments on the combination, shall be calculated using one of the following methods: 
  

	 	(e)	By multiplying the Gross Sales of the combination by the fraction A/A+B, where A is the gross selling price, during the royalty paying period in question, of the
Licensed Product sold separately, and B is the gross selling price, during the royalty period in question, of the other active ingredients or components sold separately; or 

 

	 	(f)	In the event that no such separate sales are made of the Licensed Product or any of the active ingredients or components in such combination package during the royalty
paying period in question, Gross Sales, for the purposes of determining royalty payments, shall be calculated using the above formula where A is the reasonably estimated commercial value of the Licensed Product sold separately and B is the
reasonably estimated commercial value of the other active ingredients or components sold separately. Any such estimates shall be made in good faith by Licensee and reported to Tufts with the reports to be provided to Tufts pursuant to
Section 3.7 hereof. 

 1.8. “Subsidiary” shall mean any corporation, partnership, or other business
organization that directly or indirectly controls, is controlled by, or is under common control with Licensee. For the purpose of this Agreement, “control” shall mean the holding directly or indirectly of fifty percent (50%) or more
of the voting stock or other ownership interest of the corporation or other business organization invoiced. 
 1.9.
“Territory” shall mean the world. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 3 

 ARTICLE II - GRANT; SUBLICENSES. 

2.1. Grant. Subject to the terms and conditions hereinafter set forth, Tufts hereby grants to Licensee, to the extent that it
lawfully may, a royalty-bearing, exclusive license to practice the Patent Rights and use the Technology in the Territory, only for the purpose of developing, making, using, and selling Licensed Products (the “License”). The License shall
exist as such an exclusive, royalty-bearing license during and will terminate as such at the end of the License Period, unless sooner terminated as hereinafter provided. If the License does not terminate before the end of the License Period, then
the License to use the Technology shall continue in effect thereafter without limitation of time as an exclusive, fully-paid-up license subject to termination only as provided in Article IX. 

2.2. Reserved Rights. During the License Period, Tufts shall have no right to use the Patent Rights or Technology to make, use, or
sell Licensed Products for commercial purposes, but Tufts reserves to itself (a) the right at all times to practice the Patent Rights and to use the Technology, and to make and use Licensed Products for research purposes within Tufts, and
(b) all other rights not granted to Licensee, including the rights to use and permit the use of Patent Rights and Technology for any purpose not in conflict with the provisions of the License. 

2.3. Sublicenses. Licensee shall also have the right to grant to its Subsidiaries or other sublicensees, exclusive or non-exclusive sublicenses under the License during the License Period; provided, however, and Licensee agrees that: 
 (a) the terms and conditions of each sublicense shall be consistent with the terms and conditions of this Agreement and shall contain, among other things (by way of example but not limitation), provisions
substantially similar to and consistent with: the “Gross Sales” definition; Article III (providing, among other things, that royalties shall be paid to Licensee in amounts at least equal to those of Article III hereof, so that Licensee may
in turn pay those royalties to Tufts); Article V; Section 7.1 (so that no representations or warranties inconsistent with that Article shall be extended to or by any sublicensee); Article IX, but the sublicense must terminate not later than the
end of the License Period, or earlier if the License terminates earlier for any reason; Article XI; and Article XII. 
 (b) each
sublicense shall provide that the obligations to Tufts of Sections 3.8, 3.9, 3.10, 7.1, 8.1, 8.5, and 9.2, and Articles V, XI, and XII of this Agreement shall be binding on the sublicensee and be enforceable both by Tufts and the Licensee.

 (c) if a proposed sublicensee is either (i) a Subsidiary or (ii) a company engaged in the development, manufacture
or distribution of health care products with a net worth or market capitalization of at least $50 million, no approval of Tufts shall be required for the proposed sublicense: in all other cases, the sublicense may not be granted without Tufts’
prior written approval (which may not be unreasonably withheld or delayed); 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 4 

 (d) Licensee shall furnish to Tufts a true and complete copy of each sublicense agreement
and each amendment thereto, promptly after the sublicense or amendment has been agreed upon; 
 (e) no Subsidiary or other
sublicensee shall have the right to further license, sublicense, or assign its rights without the prior approval of Licensee; and 
 (f) no sublicense shall relieve Licensee of any of its obligations hereunder, and Licensee shall be responsible for the acts or omissions of its Subsidiaries and sublicensees and for compliance by them
with their obligations, and Licensee shall take all steps necessary to enforce that compliance to the extent required to allow Licensee to fully comply with all of its obligations under this agreement. 

2.4 During the term of this Agreement and so long as neither Licensee nor any Subsidiary or sublicensee is in default with respect to any
payment due to Tufts hereunder, Tufts will not assert its rights under any Patent Rights to prevent any party from using or selling any quantity of Licensed Product on which a royalty has been paid hereunder. 

ARTICLE III - PAYMENTS; RECORDS. 
 3.1. License Fee. As partial consideration for the licenses granted hereunder, Licensee agrees to issue to Tufts and its designees, within thirty (30) days of the Effective Date, 500,000
shares of Licensee’s Common Stock, par value $0.001 per share, pursuant to the terms of a Stock Subscription and Right of First Refusal Agreement. 
 3.2. Milestone Payments. Licensee agrees to pay to Tufts the following nonrefundable milestone payments: 
  

					
	 Milestone
	  	Payment Amount	 
		
	 Commencement of First Phase III
	  	 	50,000	  
	 Clinical Trials in The United States
	  			
		
	 [***]
	  	 	[***	] 
		
	 [***]
	  	 	[***	] 

 3.3 Minimum Royalties. Licensee agrees to pay to Tufts a minimum royalty payment of Twenty-Five
Thousand Dollars ($25,000) in each twelve-month period commencing on each anniversary of the Effective Date if during such period Licensee is not sponsoring at least One Hundred Thousand Dollars ($100,000) in research at Tufts. Minimum royalty
payments shall be creditable against royalties due under Section 3.4 during the same twelve-month period. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 5 

 3.4. Running Royalties. Licensee agrees to pay to Tufts royalties of: 

(a) [***] percent ([***]%) of the Gross Sales of Licensed Products, the making, using, or selling of which infringes (were it not for the
License) at least one claim in an issued, unexpired and non-lapsed patent included in the Patent Rights; or 
 (b) [***]percent ([***]%) of the Gross Sales of Licensed Products that do not fall within the clause (a), above, but the manufacture, use or sale of which would infringe (were it not for the License) at
least one claim in a pending application included in the Patent Rights, if such claim were to issue. 
 3.5 Sublicense
Royalties. For each sublicense granted by Licensee, Licensee shall pay to Tufts (a) [***] percent ([***]%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee which are reasonably attributable to
sublicenses of rights granted to Licensee hereunder, and (b) the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by
a claim contained in an issued Patent Right or a claim included in a pending application covering a Patent Right on a country-by-country basis or (ii) the royalty
which would be due if Licensee, rather than the sublicensee, had sold the Licensed Product. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product development-related performance milestones, or for
equity investments in Licensee will not be subject to any royalties hereunder. 
 3.6 Royalty Reductions. In the event
Licensee or a sublicensee of Licensee incurs expenses in judicial or administrative proceedings based upon allegations of infringement by Licensee or sublicensee of third-party patents or know-how solely or
primarily as a result of the sale of Licensed Products, Licensee may withhold up to [***] percent ([***]%) of the royalties due hereunder for the calendar year in which the expenses are incurred, and apply the same toward reimbursement of its
expenses in connection therewith. 
 3.7. Statements; Payments. After the first commercial sale of a Licensed Product,
Licensee shall, within sixty (60) days after the last days of March, June, September, and December in each year or portion thereof during the License Period, and within sixty (60) days after the end of the License Period, provide Tufts
with a statement accounting for the Gross Sales of Licensed Products by Licensee, its Subsidiaries, and its sublicensees and all amounts described in Section 3.5, all for the immediately preceding three (3) month period or portion thereof,
accompanied by payment for the full amount of royalties due under this Article III for that period or portion thereof. Each such statement shall be certified by the Chief Financial Officer of Licensee as being true, correct, and complete.

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 6 

 3.8. Currencies. All payments to be paid to Tufts shall be computed and made in
United States Dollars, and Licensee shall use best efforts to convert royalty payments payable on Gross Sales in any country to United States Dollars; provided, however, that if conversion to and transfer of such Dollars cannot be made by Licensee,
its Subsidiaries, or its sublicensees in any country for any reason, Licensee may pay such sums in the currency of the country in which such Gross Sales are made, deposited in Tufts’ name in a bank designated by Tufts in any such country. The
rate of exchange of local currencies to U.S. Dollars shall be at the rate of exchange prevailing at the Bank of Boston (or such other bank in Boston, Massachusetts or New York, New York as Tufts may designate in writing from time to time), for
currencies of the amounts involved, as such rate is stated for the first business day after the end of the period with respect to which the royalties are due. 
 3.9. Records; Audits. Licensee shall keep (and cause to be kept) and maintain complete and accurate records of Gross Sales of the Licensed Products by Licensee, its Subsidiaries, and its
sublicensees, in accordance with generally accepted accounting procedures. Such records shall be accessible to independent certified public accountants selected by Tufts and reasonably acceptable to Licensee, by audits conducted not more than once a
year during the License Period and for one year after the termination thereof, at any reasonable times during business hours, for the purpose of verifying Gross Sales and any royalties due thereon. Such accountants shall disclose to Tufts only
information relating to the accuracy of the records kept and the payments made, and shall be under a duty to keep confidential any other information obtained from such records. Licensee, its Subsidiaries, and its sublicensees shall not be required
to retain such records for more than three (3) years after the close of any calendar quarter-year. No period shall be subject to audit under this Section more than once as to any entity being audited. 

3.10. Substantial Underpayment. If any such audit reveals that the aggregate of royalties paid during any four consecutive
calendar quarters was more than five percent (5%) less than the amount that should have been paid, then the reasonable expenses of the audit shall be borne by Licensee, which shall pay those expenses within thirty (30) days after demand
therefore by Tufts accompanied by the accountants’ statement therefor. 
 ARTICLE IV - TECHNOLOGY DISCLOSURE; PATENT
PROSECUTION. 
 4.1. Demonstration. Within ninety (90) days of the Effective Date, Tufts representative(s)
having knowledge of the Technology and Patent Rights will disclose them to Licensee personnel generally competent in the Field of Use, at the premises of Tufts, or, if mutually agreed, at the premises of Licensee. Such disclosure shall be scheduled
at the mutual convenience of Tufts and Licensee and shall be made in such ways as the parties mutually agree seems most likely to enable those Licensee personnel to learn the Technology and Patent Rights. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 7 

 4.2. Written Disclosure. Tufts may elect to prepare and furnish to Licensee one or
more written descriptions of the Technology and Patent Rights or portions thereof. Licensee agrees to review the written descriptions promptly after receiving them and indicate in writing to Tufts whether there are any details or aspects with which
Licensee does not concur. Absent a sufficiently detailed objection by Licensee, those written descriptions will be deemed binding on the parties for all purposes under this Agreement as to the description of the Technology and Patent Rights so
described. 
 4.3. Availability. Tufts shall perform its obligations under Sections 4.1 and 4.2 for no additional
consideration. Tufts shall not be obligated to devote any particular amount of time to the performance of those obligations as long as Tufts makes its knowledgeable personnel available to competent Licensee personnel as stated above, and devotes the
amount of time reasonably required to teach the necessary Technology to those Licensee personnel. Licensee agrees to make those personnel available for instruction within the time period and otherwise as stated in Section 4.1. 

4.4. Patent Prosecution. Commencing on the Effective Date, Licensee shall have the responsibility to apply for, seek prompt
issuance of, and maintain while the License is in effect, the Patent Rights in the United States, in the foreign countries listed on Exhibit B hereto and in the foreign countries selected by Licensee and Licensee will keep Tufts informed of the
foregoing on a current basis. Upon Tufts’ request, Licensee will file and prosecute patent applications corresponding to the Patent Rights in any one or more other countries, to the extent commercially reasonable. Tufts shall cooperate fully
with Licensee and provide all such information and data and execute any documents reasonably required in order to allow Licensee to conduct such prosecution and Tufts shall have the opportunity to provide substantive review and comment on any such
filing or prosecution. The choice of patent counsel shall be reasonably acceptable to Tufts. 
 4.5. Patent Expenses.
Licensee shall pay all costs associated with the preparation, filing, prosecution, and maintenance of all patent applications filed and patents obtained, which are included in the Patent Rights. 

4.6 Abandonment. In the event that Licensee desires to abandon any patent or patent application within the Patent Rights in any
country, Licensee shall provide Tufts with reasonable prior written notice of such intended abandonment or decline of responsibility, and Tufts shall have the right, at its expense, to prepare, file, prosecute, and maintain the relevant Patent
Rights. If Licensee decides to abandon an issued patent (and all filed applications therefor) throughout the world, or if Licensee determines not to file and prosecute in at least one country a patent application that Tufts has requested Licensee to
file, then in any such event such patent and patent applications shall not thereafter be included in “Patent Rights”, and the non-public information included in (or that would be included in) such
patent and applications shall not thereafter be included in “Technology”. If Licensee decides to abandon an issued patent (or a filed application therefor) in any country, or if Licensee declines to file

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 8 

 
and prosecute a patent application in a country as requested by Tufts herein, then in any such event each such country shall no longer be included in the “Territory” for purposes of the
claims covered by the relevant patent or patent application or for purposes of the non-public information included in (or that would be included in) such patent or application. 

ARTICLE V - CONFIDENTIALITY. 
 5.1. Limitations on Use, Disclosure. Licensee agrees to treat as confidential, and to use and disclose only in furtherance of this Agreement, all Confidential Technology disclosed to it by Tufts.
Licensee agrees that it will exercise every reasonable precaution to prevent the unauthorized disclosure of Confidential Technology by any of its directors, officers, employees, or agents to other parties, other than to Subsidiaries and to Licensee
sublicensees. Any Confidential Technology disclosed to Subsidiaries or sublicensees shall be disclosed on the basis of and subject to the confidentiality provisions of this Agreement. 

5.2. Cessation. Any information which is Confidential Technology at the date of disclosure thereof to Licensee shall cease to be
Technology, and Licensee, its Subsidiaries, and its sublicensees shall be released from the provisions of Section 5.1 as to such information on the date when, through no act or omission on the part of Licensee, its Subsidiaries, or its
sublicensees, such information becomes (a) publicly known by way of a single publication in which such Confidential Technology is disclosed in reasonable detail, (b) so widely known and used in combination that it can be said to be
generally available to the public or (c) is subsequently rightfully obtained without restriction on use or disclosure from sources other than Tufts having no confidential obligation in favor of Tufts. 

5.3. Time Limit. The provisions of this Article V shall continue to apply to any information which is Confidential Technology for
so long as it shall remain such, notwithstanding any termination of this Agreement or the License or expiration of the License Period, provided, however, that the obligations of confidentiality under this Article shall in any event expire and cease
to exist ten years from the Effective Date. 
 ARTICLE VI - DILIGENCE. 

Licensee agrees to use its best efforts to effect introduction of Licensed Products into the United States commercial market as soon as
practical, consistent with sound and reasonable business practices and judgments. Prior to the first commercial sale of a Licensed Product, Licensee shall provide annual reports of such efforts to Tufts within sixty (60) days of each
anniversary of the Effective Date. Tufts shall have the right, at any time after eighteen (18) months from the Effective Date, to terminate the License and Tufts’ obligations under this Agreement if Licensee, within ninety (90) days
after written notice from Tufts of such intended termination, fails to provide written evidence that Licensee has commercialized or is actively attempting to commercialize Licensed Products. Evidence that Licensee has, within eighteen months after
the Effective Date, (i) delivered to Tufts a business plan, (ii) taken all reasonable 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 9 

 
steps to prosecute and maintain the Patent Rights in accordance with the provisions of Section 4.4 hereof, (iii) made payment of all research support under the Sponsored Research
Agreement between the parties of even date herewith and (iv) raised a total of $2 million through venture capital investors or strategic partners shall be deemed, in and of itself, a sufficient showing of such active attempts to commercialize
Licensed Products during such period. Thereafter, evidence that Licensee has achieved the following milestones as scheduled below shall be deemed, in and of itself, a sufficient showing of such active attempts to commercialize Licensed Products
through such date: 
  

	 	(i)	raised a total of $5 million through venture capital investors or strategic partners within three (3) years of the Effective Date; and 

 

	 	(ii)	filed an IND for a Licensed Product in the United States within five (5) years of the Effective Date. 

Tufts shall not unreasonably withhold its assent to any revision of such milestones whenever requested in writing by Licensee and
supported by evidence of technical difficulties or delays that the parties could not have reasonably avoided. 
 Notwithstanding
the foregoing, Tufts shall have the right at any time after ten (10) years from the Effective Date to convert the License hereunder to non-exclusive if Licensee, its Subsidiaries, or its sublicensees have
not by the time of such conversion sold Licensed Products into the United States market. 
 If at any time Licensee decides to
discontinue all programs relating to the MAR operon or all programs relating to tetracycline derivatives, Licensee shall give notice of such intent to Tufts and Tufts shall have the option to terminate the License granted hereunder solely with
respect to such discontinued programs on thirty days notice to Licensee. Upon any such termination, responsibility for the prosecution and maintenance of any Patent Rights on the discontinued programs shall revert to Tufts. 

ARTICLE VII - REPRESENTATIONS, WARRANTIES, AND LIMITATIONS. 

7.1 Tufts Disclaimer. TUFTS MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED (INCLUDING,
WITHOUT LIMITATION, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR PURPOSE), AND ASSUMES NO RESPONSIBILITIES WHATSOEVER, WITH RESPECT TO THE PATENTS OR TECHNOLOGY OR THE USE THEREOF, OR THE MANUFACTURE, POSSESSION, USE, MARKETING, SALE, OR OTHER
DISPOSITION BY TUFTS, LICENSEE, OR ANYONE ELSE, OF LICENSED PRODUCT(S) OR ANY OTHER PRODUCTS OF SERVICES (INCLUDING, WITHOUT LIMITATION, PRODUCTS MADE BY TUFTS, AND TUFTS SERVICES, THAT ARE OR WERE FURNISHED TO LICENSEE AT ANY TIME BEFORE, ON, OR
AFTER THE Effective 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 10 

 
Date), EXCEPT ONLY AS EXPRESSLY STATED BELOW IN THIS ARTICLE VII. Without limitation of the foregoing generality, nothing contained herein or in any disclosure of the Patents or Technology made
by or on behalf of Tufts shall be construed as extending any representation or warranty with respect to the Patents or Technology or Licensed Products or the results to be obtained by the use of the Patents or Technology or any Licensed Products, or
that anything made, used, or sold by use of the Patents or Technology or any part thereof, alone or in combination, will be free from infringement of patents of third parties. TUFTS SHALL NOT BE LIABLE TO LICENSEE, ITS SUBSIDIARIES, ITS
SUBLICENSEES, OR ANY OTHER PARTY, REGARDLESS OF THE FORM OR THEORY OF ACTION (WHETHER CONTRACT, TORT, INCLUDING NEGLIGENCE, STRICT LIABILITY, OR OTHERWISE), FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER EXTRAORDINARY DAMAGES ARISING
OUT OF OR RELATED TO THIS AGREEMENT, PATENTS, THE TECHNOLOGY, THE LICENSED PRODUCTS, OR ANY PRODUCTS OR SERVICES FURNISHED OR NOT FURNISHED BY TUFTS, EVEN IF TUFTS HAS BEEN ADVISED OF THE POSSIBILITY THEREOF. 

Licensee agrees that all warranties, if any, in connection with the sale or other disposition of any Licensed Products (or any products
made by Tufts and furnished at any time to Licensee) by Licensee, its Subsidiaries, or its sublicensees will be made by them and will not directly or impliedly obligate Tufts. 
 7.2 Tufts Representations. Notwithstanding the first sentence of Section 7.1, Tufts: 
 (a) Represents that Tufts is a corporation organized and existing under the laws of the Commonwealth of Massachusetts and has the power and authority to enter into this Agreement. 

(b) Represents that Tufts has taken all necessary action to authorize its execution and delivery of this Agreement by the representatives
of Tufts who carried out such execution and delivery, and to authorize the performance by Tufts of its obligations hereunder. 

(c) Represents that execution and delivery of this Agreement and its performance by Tufts will not result in any breach or violation of,
or constitute a default under, any agreement, instrument, judgment, or order to which Tufts is a party or by which it is bound. 

7.3. Licensee Representations. Licensee represents and warrants to Tufts that: 

(a) Licensee is a corporation organized and existing under the laws of Delaware and has the power and authority to enter into this
Agreement. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 11 

 (b) Licensee has taken all necessary action to authorize its execution and delivery of this
Agreement by the representatives of Licensee who carried out such execution and delivery, and to authorize the performance by Licensee of its obligations hereunder. 
 (c) Execution and delivery of this Agreement and its Agreement and its performance by Licensee will not result in any breach or violation of, or constitute a default under, any agreement, instrument,
judgment, or order to which Licensee is a party or by which it is bound. 
 ARTICLE VIII - INDEMNITY; INSURANCE; INFRINGERS.

 8.1. Indemnity. Licensee agrees to exonerate, indemnify, and hold harmless Tufts, its trustees, officers,
employees, and agents, from all costs, expenses (including attorneys’ fees), interest, losses, obligations, liabilities, and damages paid or liability for which is incurred by any of said parties (“Losses”), and which arise out of or
are in connection with or are for the purpose of avoiding any and all claims, demands, actions, causes of action, suits, appeals, and proceedings (“Claims”), all whether groundless or not, or the settlement thereof, based on any actual or
alleged injuries, damages, or liability of any kind whatsoever (including, without limitation, personal injury, death, property damage, breach of warranty, or breach of contract) arising, directly or indirectly, out of any one or more of: any breach
of Licensee of its representations, warranties, or agreements hereunder; or out of any manufacture, marketing, possession, use, sale, or other disposition of Licensed Products or products furnished by Tufts to Licensee in connection herewith or in
connection with the Research Agreement (whether same occurs during or after the License or during or after the License Period) by Licensee, its Subsidiaries, its sublicensees, or anyone claiming by, through, or under any of them; or any acquisition,
possession, disclosure, or use of the Patents or Technology, or any thereof, by Licensee, its Subsidiaries, its sublicensees, or anyone claiming by, through, or under any of them or the presence of Licensee’s or its Subsidiaries’ or
sublicensee’s officers, agents, employees, invitees or property on Tufts’ premises. 
 8.2. Defense;
Settlement. Licensee shall defend and control negotiation of settlement of any Claim, with counsel of Licensee’s choosing approved in advance by Tufts, which approval shall not be unreasonably withheld. Tufts agrees to cooperate fully in
the defense of any Claim and may participate in the defense with counsel of Tufts’ choosing, such separate counsel to be at Tufts’ expense unless a conflict of interest exists between Licensee and Tufts with respect to the defense, in
which case Tufts’ separate counsel shall be at Licensee’s expense. Any settlement by which Tufts would incur any obligation or liability, whether for the payment of money, the taking of any action, the refraining from any action, or
otherwise, shall require the advance written consent of Tufts, which may be withheld in the sole discretion of Tufts without relieving Licensee of any of its indemnification or other obligations hereunder. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 12 

 8.3. Insurance. Not later than thirty (30) days before the time when Licensee,
any Subsidiary, or any Licensee sublicensee shall, on a commercial basis, make, use, or sell any Licensed Products or any products furnished to Licensee by Tufts at any time (before, on or after the Effective Date) in connection herewith or in
connection with the Research Agreement, and at all times thereafter until the expiration of all applicable statutes of limitation pertaining to any such manufacture, marketing, possession, use, sale or other disposition of any Licensed Products or
the aforesaid products furnished by Tufts (whether same occurs or exists during or after the existence of the License or during or after the License Period), Licensee will at Licensee’s expense, obtain and maintain in full force and effect,
comprehensive general liability insurance, including product liability insurance, protecting Tufts against all claims, suits, obligations, liabilities, and damages, based upon or arising out of actual or alleged bodily injury, personal injury,
death, or any other damage to or loss of persons or property, caused by any such manufacture, marketing, possession, use, sale, or other disposition. Such insurance policy or policies shall be issued by companies rated by A. M. Best as A VIII or
better (or other companies acceptable to Tufts), shall name Tufts as an additional named insured, shall have limits of at least one million dollars ($1,000,000) per occurrence with an aggregate of three million dollars ($3,000,000), shall be non-cancelable except upon thirty (30) days prior written notice to Tufts, and shall provide that as to any loss covered thereby and also by any policies obtained by Tufts itself, Licensee’s policies shall
provide primary coverage for Tufts and Tufts’ policies shall be considered excess coverage for Tufts. 
 8.4.
Certificates: Policies. Licensee will forthwith after the obtaining of such insurance required by Section 8.3, obtain and deliver to Tufts certificates of and copies of, and at all times thereafter deliver without further demand
replacement certificates and copies of, all such insurance policies that are in force and effect. As requested by Tufts but in no event more than once per calendar year, Licensee will furnish to Tufts a complete list, statement, and description of
all insurance called for in this Article, together with certificates and copies of policies for each insurance company issuing any thereof, that such insurance in is full force and effect, that all premiums have been paid, and that such insurance
will not be canceled except upon thirty (30) days prior written notice to Tufts. 
 8.5. Infringers. Each party
shall inform the other promptly in writing of any alleged infringement of the Patent Rights in the Field of Use by a third party, including all details then available. Licensee shall have the right, but shall not be obligated, to prosecute at its
own expense any such infringements, and Tufts agrees that Licensee may join Tufts as a plaintiff at the expense of Licensee. In any infringement action commenced solely by Licensee, all expenses of Licensee shall first be reimbursed and all recovery
for infringement shall be shared [***]% to Tufts and [***]% to Licensee. Licensee shall indemnify Tufts against any order for costs or other payments that may be made against Tufts in such proceedings. 

If Licensee has not taken legal action or been successful in obtaining cessation of the infringement, within one-hundred eighty (180) days of written notification from Tufts of such infringement, or if Licensee elects not to continue prosecuting any legal action against an

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 13 

 
infringer, Tufts shall have the right, but shall not be obligated, to prosecute at its own expense any such infringement. Tufts may join Licensee as a plaintiff in any such infringement suit at
Tufts’ expense. In any such action by Tufts, all expenses of Tufts shall first be reimbursed and all recovery for infringement shall be shared [***]% to Tufts and [***]% to Licensee. 

No settlement, consent judgment or other voluntary final disposition of any suit may be entered into without the consents of Tufts and
Licensee, which consents shall not be unreasonably withheld or delayed. 
 In any infringement suit that either party brings to
enforce the Patent Rights, the other party shall at the request and expense of the party bringing the suit, cooperate in all reasonable respects, including, to the extent possible, obtaining the testimony of its employees and making available
physical evidence in the possession of that party. 
 Licensee shall have the exclusive right in accordance with the provisions
of Section 2.2, to sublicense any alleged infringer in the Territory for the Field of Use, for future use of the Patent Rights. 
 8.6 Declaratory Judgment. If any declaratory judgment action alleging invalidity or non-infringement of any of the Patent Rights shall be brought against
Licensee, Tufts shall have the right at its election made within sixty (60) days after commencement of that action, to intervene and take over the sole defense of the action at its expense. 

ARTICLE IX - LICENSE TERMINATION. 
 9.1. Events. The License granted hereunder may be terminated by Tufts pursuant to Article VI or one of the following subsections: 

(a) Material Default. If Licensee shall fail after thirty (30) days written notice from Tufts to pay to Tufts any royalties
or other payments and payable hereunder, or shall fail in any material way to perform any other agreement required to be performed by Licensee under this Agreement, or if any Subsidiary or sublicensee shall be in material breach of any conditions or
obligations affecting Tufts and compliance with which Licensee is responsible for hereunder, or if any representation or warranty of Licensee contained in this Agreement shall prove to have been inaccurate or misleading in any material way when made
(referred to collectively and individually as a “material default”), then, without limitation of and in addition to any and all other rights and remedies available to Tufts with respect to such material default, Tufts may terminate the
License and Tufts’ obligations hereunder by written notice to Licensee at any time after the expiration of such thirty (30) day notice period if Licensee has not cured the material default and the effects thereof before Tufts gives such
notice of termination to Licensee, unless Licensee commences arbitration proceedings hereunder to contest such material default, in which event Tufts’ right to terminate the License shall be stayed until such arbitration proceedings shall have
been completed. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 14 

 (b) Cessation of Business. If Licensee shall have commenced to carry on the business
of selling any Licensed Products (either directly or through any Subsidiary or sublicensee) and shall at any time thereafter cease for a consecutive period of ninety (90) days to carry on such business actively (either directly or through any
Subsidiary or sublicensee), other than as a result of fire or other casualty or governmental action taken in the absence of Licensee’s fault, Tufts may at any time thereafter while that state of affairs continues, terminate the License by
written notice to Licensee. 
 9.2 Licensee shall have the option at any time to terminate this License upon one-hundred and eighty (180) days’ written notice to Tufts. 
 9.3. Effects.
Upon termination of the License for any reason, nothing herein shall be construed to release Licensee from any obligations hereunder except those of Article VI, but all rights of Licensee and its Subsidiaries and its sublicensees to make, use, or
sell Licensed Products, or to practice the Patents and use the Technology, shall cease immediately, except that Licensee, its Subsidiaries, and its sublicensees may after the effective date of such termination sell all Licensed Products that they
may have on hand at the date of termination, and may complete manufacture of Licensed Products then in the process of manufacture, and sell them, provided that they pay all royalties due thereon with respect to Gross Sales, as provided in this
Agreement. 
 ARTICLE X - NOTICE. 
 Any notice or communication required to be given hereunder in writing shall be given by registered or certified mail, return receipt requested, or delivered by courier, return receipt requested, charges
and postage prepaid, addressed to the parties, respectively, at the following addresses: 
 In the case of Tufts to: 

Joseph J. Byrne, Ph.D. 
 Associate Provost for Research 
 Tufts University 

136 Harrison Avenue 
 Boston, MA 02111 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 15 

 with a copy to: 
 Mason (Skip) Irving, III 
 Vice President, Commercial Development 

Massachusetts Biotechnology Research Institute 
 One Innovation Drive 
 Worcester, MA 01605 

with a second copy to: 
 Mary
Lee Jacobs, Esq. 
 General Counsel 
 Tufts University 
 Ballou Hall 

Medford, MA 02155 
 or in the
case of Licensee to: 
 Walter Gilbert 
 Acting Chief Executive Officer 
 Paratek Pharmaceuticals, Inc. 

P.O. Box 1525 

Boston, MA 02117-1525 
 with a
copy to: 
 Jeffrey M. Wiesen, Esq. 
 Mintz, Levin, Cohn, Ferris, 
   Glovsky & Popeo P.C. 

One Financial Center 
 Boston, MA 02111 
 or at such other respective substitute addresses as the addressee may designate
in writing to the other party. 
 ARTICLE XI - NON-USE OF NAMES. 

Licensee, its subsidiaries and its sublicensees agree that it will not use the name “Tufts University,” or any variant thereof,
or identify Tufts or any portion of Tufts, or any inventor of any of the Patents or Technology, as a party to this Agreement, or as a participant in inventing the inventions of the Patents or creating the Technology, including, without limitation,
in any advertising or promotional sales literature, without the prior express written consent of Tufts, which consent may be withheld or withdrawn by Tufts in its complete and 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 16 

 
uncontrolled discretion for any reason whatsoever and at any time or times. However, notwithstanding the foregoing, Tufts will make no objection to any proper reference by Licensee to published
technical publications by such inventors or creators; and, subject to the confidentiality requirements hereof, Tufts will make no objection to Licensee’s making such disclosures as in the reasonable opinion of legal counsel are required as a
matter of law and such general disclosures of this Agreement as may be desired by Licensee for purposes of grant solicitations from governmental authorities or as reasonably necessary (as reasonably determined by Licensee) for the purposes of
obtaining financing for Licensee or as reasonably necessary (as reasonably determined by Licensee) for the conduct of its business, other than advertising or sales promotion. Licensee shall impose and enforce the requirements of this Article on its
Subsidiaries and sublicensees. 
 ARTICLE XII - COMPLIANCE WITH LAWS. 

12.1. Export Controls. The Export Control Regulations of the U. S. Department of Commerce prohibit, except under special
validated license, the exportation from the United States of technical data relating to certain commodities (listed in the Regulations), unless the exporter has received certain written assurance from the foreign importer. In order to facilitate the
exchange of technical information under this Agreement, Licensee therefore hereby agrees and gives its assurance to Tufts that Licensee will not, unless any required prior authorization is obtained from the U. S. Office of Export Control, re-export directly or indirectly any technical data received from Tufts under this Agreement and will not export directly the Licensed Products or such technical data to any country listed on either the Commodity
Control List or Militarily-Critical Technologies List. Tufts makes no representation as to whether any such license is required or, if one is required, as to whether it will be issued by the U. S. Department of Commerce. 

12.2. Other Laws. In addition to the foregoing export control requirements, Licensee agrees that it, its Subsidiaries, and its
sublicensees will comply with all applicable mandatory or permissive patent marking laws, rules, and regulations and comply with all other laws, rules, and regulations of all governmental authorities applicable to any of their activities
contemplated by this Agreement, and will comply with all necessary and desirable practices in connection and compliance with safety recommendations of trade associations or governmental authorities. 

ARTICLE XIII - MISCELLANEOUS PROVISIONS. 
 13.1. Assignment. Licensee shall not assign the License or this Agreement without the prior written consent of Tufts, which consent shall not be unreasonably withheld; provided, however, that
Licensee, without such consent, may assign all of its rights hereunder to a wholly-owned Subsidiary or to the acquiring party in connection with the transfer of all or substantially all of its business and assets to an acquiring party or in the
event of its merger or consolidation with that acquiring party, if and only if the assignee shall assume all obligations 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 17 

 
of Licensee under this Agreement. However, no assignment or other transfer by Licensee shall relieve Licensee of any obligations hereunder and Licensee shall continue to be primarily and jointly
and severally liable (along with such assignee or other transferee) for the performance of all obligations of Licensee and such assignee or other transferee hereunder. 
 13.2. Independent Contractors. The parties hereto shall be independent contractors with respect to each other, and nothing contained herein shall be construed as constituting either of them as the
agent, principal, employee, servant, joint venturer, or partner of the other for any purpose whatsoever. 
 13.3 Governing
Law. This Agreement shall be governed by and construed in accordance with Massachusetts law, without regard to its conflict of laws principles. 
 13.4. Sole Agreement. This Agreement and any Exhibits annexed hereto (each of which is hereby made part hereof by this reference), and any other documents which may be expressly incorporated by
reference herein, constitute the entire and only agreement between the parties concerning the subject matter hereof; and all prior negotiations, representations, warranties, agreements, and understandings related thereto are superseded hereby.

 13.5. Severability. If any provision of this Agreement shall to any extent be found to be invalid
or unenforceable, the remainder of this Agreement shall-not be affected thereby, and any such invalid or unenforceable provision shall be reformed so as to be valid and enforceable to the fullest extent permitted by law. 

13.6. Headings. Headings of Articles, Sections, and subsections included herein are for convenience of reference only and shall
not be used to construe this Agreement. 
 13.7. Financial Confidentiality. Both parties agree to keep the financial
terms of this Agreement confidential. 
 ARTICLE XIV - ARBITRATION. 

14.1. Arbitration. Subject to Section 14.2 below, all disputes, controversies, or differences which may arise between the
parties out of or in relation to or in connection with this Agreement, or for the breach thereof, which cannot be resolved by mutual agreement, shall be finally settled by arbitration to be held in accordance with the Commercial Arbitration Rules
(the “Rules”) of the American Arbitration Association (the “Association”) as the Rules then exist, in Boston, Massachusetts, with the following deviations from the Rules. The arbitrators shall consist of one Tufts nominee, one
Licensee nominee, and a third person jointly selected by those two nominees. The party requesting arbitration shall designate its nominee in the request, which shall be addressed to the Association with a simultaneous copy to the other party. If the
other party shall fail within thirty (30) days of the request for arbitration to nominate the second arbitrator or if the two arbitrators are unable to agree upon the third 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 18 

 
arbitrator within thirty (30) days after selection of the second arbitrator, then in either case the arbitration panel will be completed according to the Rules. Both legal and equitable
remedies shall be available to the arbitrators. The award of a majority of the arbitration panel shall be final and binding on the parties hereto and shall be enforceable in any court having jurisdiction. Tufts and Licensee each irrevocably consent
and submit to the jurisdiction of the courts of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts. 
 14.2. Judicial Relief. Claims, disputes, or controversies concerning the validity, infringement, construction, or effect of any patent including, without limitation, any patent licensed hereunder,
shall be resolved in any court having jurisdiction thereof, and the parties submit to the jurisdiction of the United States District Court for the District of Massachusetts. In the event that, in any arbitration proceeding, any issue shall arise
concerning the validity, infringement, construction, or effect of any patent licensed hereunder, the arbitrators shall assume the validity of all claims as set forth in such patent. In any case, the arbitrators shall not delay the arbitration
proceeding for the purpose of obtaining or permitting either party to obtain judicial resolution of such an issue, unless an order staying such arbitration proceeding shall be entered by a court of competent jurisdiction. Neither party shall raise
any issue concerning the validity, infringement, construction, or effect of any patent licensed hereunder in any proceeding to enforce any arbitration award hereunder in any proceeding otherwise arising out of any such arbitration award. Nothing in
Section 14.1 shall be construed to waive any rights or timely performance of any obligations existing under this Agreement. Moreover, each party acknowledges that appropriate cases (as determined by the courts of competent jurisdiction) of a
violation by either party of any of the provisions of this Agreement may entitle the other party to equitable judicial relief, and this relief shall be available in addition to, and shall not be unavailable by reason of, the arbitration provisions
of Section 14.1, above. Such equitable judicial relief may be by temporary restraining orders, preliminary and permanent injunctions, and such other equitable relief as any court of competent jurisdiction may deem just and proper. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 19 

 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this License
Agreement to be effective as of the Effective Date. 
  

											
	TUFTS UNIVERSITY	 		 		 	PARATEK PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Steven S. Manos
	 		 	By:	 	 /s/ Walter Gilbert

		 	Signature	 		 		 	Signature
					
	 Steven S. Manos
	 		 		 		 	  

						
		 	Typed Name	 		 		 		 	Typed Name
					
	 Executive Vice President
	 		 		 		 	  

						
		 	Title	 		 		 		 	    Title
					
	     3/19/97
	 		 		 		 	     4/23/97

						
		 	Date	 		 		 		 	    Date

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 20 

 EXHIBIT A 
 TO 
 LICENSE AGREEMENT 

BETWEEN 
 TUFTS
UNIVERSITY AND PARATEK PHARMACEUTICALS, INC. 
 Existing Patent Rights (Including Existing Applications) 

 

	 	I.	Issued Patents:            (See attached Patent Summary) 

“Patent Rights” shall also include the patents to be applied for pursuant to the terms of the License Agreement after the Effective Date, after
such applications are made. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 21 

 Patent Summary 
 Stuart B. Levy, Ph.D. 
 January 1997 

 

			
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
  
 22 

 EXHIBIT B 

List of Foreign Countries in which Patents are to be Filed. 
 United States 
 Canada 

Japan 

  Europe (Germany, Belgium, France, Italy, Spain and United Kingdom) 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 22 

 TUFTS UNIVERSITY — PARATEK PHARMACEUTICALS, INC. 

AMENDMENT NO. 1 

TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Exhibit A is hereby amended to include: 
  

	•	 	 Provisional patent application “[***]”, Filed [***] 

 

	•	 	 Patent application “[***]”, Filed [***] 

 Section 1.4. “Field of Use” is hereby replaced by the following: 
 1.4. “Medical Field of Use” shall mean the prophylaxis, treatment or prevention of bacterial or microbial diseases or medical conditions in humans or animals or agriculture through the direct
administration of (i) tetracycline derivatives or other compounds which affect tetracycline resistance or (ii) compounds based on knowledge of the MAR operon or (iii) compounds involving novel genes which affect antibiotic resistance
or microbial infectivity and which are derived from studies of the MAR operon or (iv) compounds that affect any such genes. 
 “Disinfectant Field of Use” shall mean the use of compositions, including but not limited to disinfectants and soaps, in any manner other than the direct administration to humans or animals or
agriculture, to kill or reduce the growth rate of microorganisms, where such compositions include (i) tetracycline derivatives or other compounds which affect tetracycline resistance or (ii) compounds based on knowledge of the MAR operon
or (iii) compounds involving novel genes which affect antibiotic resistance or microbial infectivity and which are derived from studies of the MAR operon or (iv) compounds that affect any such genes. 

“Field of Use” shall mean the Medical Field of Use and Disinfectant Field of Use, collectively. 

Section 1.7. Third paragraph is hereby amended to read: “In the event that a Licensed Product in the Medical Field of Use under this
Agreement is sold...” 
 Section 3.4 Running Royalties is hereby replaced by the following: 

3.4. Running Royalties. 
 For the Medical Field of Use, Licensee agrees to pay to Tufts royalties of: 
 (a)
[***] percent ([***]%) of the Gross Sales of Licensed Products, the making, using, or selling of which infringes (were it not for the License) at least one claim in an issued, unexpired and non-lapsed patent
included in the Patent Rights; or 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 1 

 (b) [***] percent ([***] %) of the Gross Sales of Licensed Products that do not fall within
the clause (a), above, but the manufacture, use or sale of which would infringe (were it not for the License) at least one claim in a pending application included in the Patent Rights, if such claim were to issue. 

For the Disinfectant Field of Use, Licensee agrees to pay to Tufts royalties of: 

[***] percent ([***]%) of the Gross Sales of Licensed Products, the making, using, or selling of which infringes (were it not for the
License) at least one claim in an issued, unexpired and non-lapsed patent included in the Patent Rights or would infringe (were it not for the License) at least one claim in a pending application included in
the Patent Rights, if such claim were to issue. 
 Section 3.5. Sublicense Royalties is hereby replaced by the following:

 3.5. Sublicense Fees and Royalties. For each sublicense granted by Licensee, Licensee shall pay to Tufts [***] percent
([***]%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee which are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a sublicensee for
research conducted by Licensee, achievement of product development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder. 

For the Medical Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts the lesser of (i) [***] percent
([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending application covering a
Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the sublicensee, had sold
the Licensed Product. 
 For the Disinfectant Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts
the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to the Gross Sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included
in a pending application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee,
rather than the sublicensee, had sold the Licensed Product. 
 All other provisions of the Agreement remain unchanged and in full force and
effect. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 2 

											
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS, INC.
						
	By:	 	 /s/ Philip G. Salem
	 		 		 	By:	 	 /s/ George C. Hillman

		 	    (signature)	 		 		 		 	    (signature)
				
	 Philip G. Salem
	 		 		 	 George C. Hillman

				
	Name	 		 		 	Name
				
	 Senior Director, University Development
	 		 		 	 Executive Vice President

				
	Title	 		 		 	Title
				
	 12/23/97
	 		 		 	 12/29/97

				
	 Date
	 		 		 	 Date

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 TUFTS UNIVERSITY — PARATEK PHARMACEUTICALS, INC. 

AMENDMENT NO. 2 

TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Exhibit A is hereby amended to include: 
  

	•	 	 Patent application entitled: “[***]” Continuation in Part of U.S. patent No.: [***], Filed [***], Notice of Allowance [***].

  

	•	 	 Provisional patent application entitled: “[***]”, Serial No.: [***], Filed [***] 

 

	•	 	 Patent application jointly owned with [***], entitled: “[***]”, Serial No.: [***], Filed [***] 

 

	•	 	 Provisional patent application entitled: “[***]”, Serial No.: [***], Filed [***] 

 

	•	 	 Patent application entitled: “[***]”, Serial No.: [***], Filed [***] 

 

	•	 	 Patent application entitled: “[***]”, U.S. patent No. [***], Issued [***], Divisional Application of U.S. patent No. [***]

 All other provisions of the Agreement remain unchanged and in full force and effect. 

 

											
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS, INC.
						
	By:	 	 /s/ Margaret Newell
	 		 		 	By:	 	 /s/ George C. Hillman

						
		 	(signature)	 		 		 		 	(signature)
				
	 Margaret Newell
	 		 		 	 George C. Hillman

				
	Name	 		 		 	Name
				
	 Executive Vice President and Associate Provost for Research
	 		 		 	 Chief Operating Officer

				
	Title	 		 		 	Title
				
	       7/31/98
	 		 		 	       7/31/98

				
	Date	 		 		 	Date

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC 

AMENDMENT NO. 3 
 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Exhibit A and all amendments and
modifications are deleted and replaced in their entirety by the attached Exhibit A. Tufts’ ownership interests in all patents, patent applications and disclosures listed in the attached Exhibit A are hereby incorporated into the License
Agreement dated February 1, 1997. 
 All other provisions of the Agreement as amended remain in full force and effect. 

IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment to be effective as of the last date of signature below.

  

									
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Margaret Newell
	 		 	By:	 	 /s/ George Hillman

		 	Margaret Newell, Associate Provost for Research	 		 		 	George Hillman, Executive Vice President
					
	Date:	 	 6/3/99
	 		 	Date:	 	 6/3/99

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 Amendment #3 - Exhibit A 

PATENT SUMMARY AS OF MAY 27, 1999 
 Stuart B. Levy, M.D. 
 Compositions and Methods Related to Antibiotic
Resistance 
  

			
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 1 – 

 Amendment #3 - Exhibit A 

PATENT SUMMARY AS OF MAY 27, 1999 
 Stuart B. Levy, M.D. 
  

 Compositions and Methods Related to Antibiotic Resistance 

 

			
	 [***]
	  	[***]
	 [***]
	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 2 – 

 Amendment #3 - Exhibit A 

PATENT SUMMARY AS OF MAY 27, 1999 
 Stuart B. Levy, M.D. 
  

 TETRACYLINE 

 

			
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 3 – 

 Amendment #3 - Exhibit A 

PATENT SUMMARY AS OF MAY 27, 1999 
 Stuart B. Levy, M.D. 
  

 COMPOSITIONS AND METHODS RELATED TO ANTIBIOTIC RESISTANCE 

DISCLOSURES 
  

			
	 [***]
	  	[***]
	 [***]
	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 4 – 

 Amendment #3 - Exhibit A 

PATENT SUMMARY AS OF MAY 27, 1999 
 Stuart B. Levy, M.D. 
  

 TETRACYCLINE DISCLOSURES 

 

			
	 [***]
	  	
	 [***]
	  	[***]
	 [***]
	  	
	 [***]
	  	
	 [***]
	  	
	 [***]
	  	
	 [***]
	  	
	 [***]
	  	
	 [***]
	  	

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 5 – 

 Amendment #3 - Exhibit A 

PATENT SUMMARY AS OF MAY 27, 1999 
 Stuart B. Levy, M.D. 
  

 TETRACYCLINE DISCLOSURES (continued) 

 

			
	 [***]
	 	
	 [***]
	 	
	 [***]
	 	

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 6 – 

 TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC 

AMENDMENT NO. 4 

TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Exhibit A and all amendments and modifications are deleted and replaced in their entirety by the attached Exhibit A. Tufts’ ownership interests in all patents, patent applications and
disclosures listed in the attached Exhibit A are hereby incorporated into the License Agreement dated February 1, 1997. Exhibit A shall hereafter be updated on an annual basis. Each new Exhibit A shall be dated and appended hereto and by such
action replace all prior versions of Exhibit A. 
 All other provisions of the Agreement as amended remain in full force and effect. 

IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment to be effective as of the last date of signature below.

  

									
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Margaret Newell
	 		 	By:	 	 /s/ George Hillman

	Margaret Newell, Associate Provost for Research	 		 		 	George Hillman, Executive Vice President
					
	Date:	 	 8/9/00
	 		 	Date:	 	 8/14/00

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

					
	Updated August 8, 2000	  	Exhibit A	  	
		  	  
 CONFIDENTIAL

ATTORNEY-CLIENT PRIVILEGED
  

PARATEK PHARMACEUTICALS, INC.
 PATENT STATUS SHEET
	  	

  

											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or

Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 1 – 

 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 

											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 2 – 

 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 

											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 3 – 

 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 

											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 4 – 

 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 

											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 5 – 

 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 

											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 6 – 

 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 

											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 7 – 

 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 

											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 8 – 

 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 

											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 9 – 

 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 

											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	
	 [***]
	  		  	[***]	  		  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  		  		  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 10 – 

 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET 

 

											
	 Docket No.
	  	 Serial No./

Patent No.
	  	 Title and Description
	  	 Inventors and/or
Contributors
	  	 Filing date/

Issue date
	  	 Status

	(Firm of Record)	  	 	  	 	  	(Owners)	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  		  		  	
	 [***]
	  		  	[***]	  		  		  	[***]
	 [***]
	  		  	[***]	  		  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 11 – 

 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET (FOREIGN)

  

											
	 Docket No.
	  	 Region/

Country
	  	 Appln. No./

Patent No.
	  	 Title and Description
	  	 Appln. Date/

Grant date
	  	 Status

	(Firm of Record)	  	 	  	 	  	 	  	 	  	 
						
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 12 – 

 CONFIDENTIAL 

ATTORNEY-CLIENT PRIVILEGED 
 PARATEK PHARMACEUTICALS, INC. 
 PATENT STATUS SHEET (FOREIGN)

  

											
	 Docket No.
	  	 Region/

Country
	  	 Appln. No./

Patent No.
	  	 Title and Description
	  	 Appln. Date/

Grant date
	  	 Status

	(Firm of Record)	  	 	  	 	  	 	  	 	  	 
						
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  		  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 13 – 

 TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC 

AMENDMENT NO. 5 

TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Exhibit A and all amendments and modifications are deleted and replaced in their entirety by the attached Exhibit A. Tufts’ ownership interests in all patents, patent applications and
disclosures listed in the attached Exhibit A are hereby incorporated into the License Agreement dated February 1, 1997. Exhibit A shall hereafter be updated on an annual basis. Each new Exhibit A shall be dated and appended hereto and by such
action replace all prior versions of Exhibit A. 
 All other provisions of the Agreement as amended remain in full force and effect. 

IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment to be effective as of the last date of signature below.

  

									
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Margaret Newell
	 		 	By:	 	 /s/ George Hillman

	Margaret Newell	 		 	George Hillman
	Associate Provost for Research	 		 	Executive Vice President
					
	Date:	 	 9/10/01
	 		 	Date:	 	 9/10/01

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 PATENT SUMMARY 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing date
	  	 Issue Date
	  	 Status

							
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 1 – 

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing date
	  	 Issue Date
	  	 Status

							
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 2 – 

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing date
	  	 Issue Date
	  	 Status

							
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 3 – 

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing date
	  	 Issue Date
	  	 Status

							
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 - 4 – 

 TUFTS UNIVERSITY - PARATEK PHARMACEUTICALS, INC 

AMENDMENT NO. 6 
 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Exhibit A and all amendments and
modifications are deleted and replaced in their entirety by the attached Exhibit A. Tufts’ ownership interests in all patents, patent applications and disclosures listed in the attached Exhibit A are hereby incorporated into the License
Agreement dated February 1, 1997. Exhibit A shall hereafter be updated on an annual basis. Each new Exhibit A shall be dated and appended hereto and by such action replace all prior versions of Exhibit A. 

All other provisions of the Agreement as amended remain in full force and effect. 
 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment to be effective as of the last date of signature below. 

 

									
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Margaret Newell
	 		 	By:	 	 /s/ George Hillman

		 		 		 		 	George Hillman
		 		 		 		 	Executive Vice President
					
	Date:	 	 12/11/02
	 		 	Date:	 	 12/11/02

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 1 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  		  		  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  		  		  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 2 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 3 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 4 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 1 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  		  		  	[***]
	[***]	  	[***]	  	[***]	  		  		  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 2 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 
 Page 3 

 TUFTS UNIVERSITY — PARATEK PHARMACEUTICALS, INC. 

AMENDMENT NO. 7 
 TO LICENSE AGREEMENT DATED FEBRUARY 1, 1997 
 Section 3.4 Running Royalties is hereby
replaced by the following: 
 3.4 Running Royalties. 
 For the Medical Field of Use, Licensee agrees to pay to Tufts royalties of: 
 (a)
[***] percent ([***]%) of the Gross Sales of Licensed Products, the making using, or selling of which infringes (were it not for the License) at least one claim in an issued, unexpired and non-lapsed patent
included in the Patent Rights; or 
 (b) [***]percent ([***]%) of the Gross Sales of Licensed Products that do not fall within
clause (a), above, but the manufacture, use, or sale of which would infringe (were it not for the License) at least one claim in a pending patent application included in the Patent Rights, if such claim were to issue. 

For the Disinfectant Field of Use, Licensee agrees to pay to Tufts royalties of: 

[***] percent ([***]%) of the Gross Sales of Licensed Products, the making using, or selling of which infringes (were it not for the
License) at least one claim in an issued, unexpired and non-lapsed patent included in the Patent Rights or would infringe (were it not for the License) at least one claim in a pending patent application
included in the Patent Rights, if such claim were to issue. 
 Section 3.5 Sublicense Royalties is hereby replaced by the following:

 3.5 Sublicense Fees and Royalties. 
 For the Medical Field of Use, Licensee agrees to make the following payments to Tufts: 
 (a) Sublicense Fees. For the Medical Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts [***] percent ([***]%) of that portion of any sublicense issue fees or
license maintenance fees received by Licensee that are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product
development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder. 

(b) Sublicense Royalties. For the Medical Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts the
lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a pending
application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather than the
sublicensee, had sold the Licensed Product. 

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 For the Disinfectant Field of Use, Licensee agrees to make the following payments to Tufts: 

(c) Sublicense Fees. For the Disinfectant Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts
[***]percent ([***]%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee that are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a
sublicensee for research conducted by Licensee, achievement of product development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder. 

(d) Sublicense Royalties. For the Disinfectant Field of Use, for each sublicense granted by Licensee, Licensee shall pay to Tufts
the lesser of (i) [***] percent ([***]%) of any royalty payments received under such sublicense with respect to sales by the sublicensee of Licensed Products covered by a claim contained in an issued Patent Right or a claim included in a
pending application covering a Patent Right on a country-by-country basis or (ii) the royalty which would be due, pursuant to Section 3.4, if Licensee, rather
than the sublicensee, had sold the Licensed Product. 
 ARTICLE VI — DILIGENCE clause (ii) of the fifth sentence is hereby
amended to read: 
 (ii) filed an IND for a Licensed Product in the United States within seven (7) years of the Effective
Date. 
 ARTICLE VI — DILIGENCE Third paragraph is hereby amended to read: “Notwithstanding the forgoing, Tufts shall have the
right at any time after twelve (12) years from the Effective Date to convert the License...” 
 Exhibit A and all amendments
and modifications are deleted and replaced in their entirety by the attached Exhibit A. Tufts’ ownership interests in all patents, patent applications and disclosures listed in the attached Exhibit A are hereby incorporated into the License
Agreement dated February 1, 1997. Exhibit A shall hereafter be updated on an annual basis. Each new Exhibit A shall be dated and appended hereto and by such action replace all prior versions of Exhibit A. 

All other provisions of the Agreement as amended remain in full force and effect. 
 IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment to be effective as of the last date of signature below. 

 

									
	TUFTS UNIVERSITY	 		 	PARATEK PHARMACEUTICALS
					
	By:	 	 /s/ Margaret Newell
	 		 	By:	 	 /s/ Thomas J. Bigger

	Margaret Newell	 		 	Thomas J. Bigger
	Associate Provost for Research	 		 	President and Chief Executive Officer
					
	Date:	 	 7/1/03
	 		 	Date:	 	 6/17/03

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (TET) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  		  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  		  		  		  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  		  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 EXHIBIT A 

CONFIDENTIAL 
 Patent Summary (MAR) 
  

													
	 L&C Docket No.
	  	 Title
	  	 Application No.
	  	 Patent No.
	  	 Billing Date
	  	 Filing Date
	  	 Status

	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]
							
	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]

  
 Portions of this Exhibit,
indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of
1933, as amended. 

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 AMENDMENT NO. 8 TO THE 
 TUFTS UNIVERSITY LICENSE AGREEMENT

 This Amendment No. 8 to the Tufts University License Agreement (this “Amendment”), dated as of
November 20, 2012 (the “Amendment Effective Date”) is by and between Paratek Pharmaceuticals, Inc. (“Licensee”), and Tufts University, a/k/a Trustees of Tufts College (“Tufts”). Each of
Licensee and Tufts is sometimes referred to individually herein as a “Party” and collectively as the “Parties”. 
 WHEREAS, the Parties entered into the Tufts University License Agreement, effective as of February 1, 1997 and entered into amendments thereto: Amendment No. 1 dated as of December 29,
1997, Amendment No. 2 dated July 31, 1998, Amendment No. 3 dated June 3, 1999, Amendment No. 4 dated August 14, 2000, Amendment No. 5 dated September 10, 2001, Amendment No. 6 dated December 11,
2002, Amendment No. 7 dated July 1, 2003 and the letter agreement dated September 17, 2009 (the “Novartis Amendment”), as so amended, the “License Agreement”; and 

WHEREAS, the Parties now wish to further amend the License Agreement as set forth herein. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows: 
  

	 	1.	Amendments to Agreement. 

(a) The definition of Field of Use in Section 1.4 of the License Agreement is hereby deleted in its entirety and the following is
hereby inserted in lieu thereof: 
 “Medical Field of Use” shall mean the prophylaxis, treatment or
prevention of all diseases or medical conditions in humans, animals and/or agriculture, including bacterial or microbial diseases, through the direct administration of (a) tetracycline derivatives or (b) compounds which affect tetracycline
resistance or (c) compounds based on knowledge of the MAR operon or (d) compounds involving novel genes which affect antibiotic resistance or microbial infectivity and which are derived from studies of the MAR operon or (e) compounds
that affect any such genes. 
 “Disinfectant Field of Use” shall mean the use of compositions,
including but not limited to disinfectants and soaps, in any manner other than the direct administration to humans or animals or agriculture, to kill or reduce the growth rate of microorganisms, where such compositions include (a) tetracycline
derivatives or (b) compounds which affect tetracycline resistance or (c) compounds based on knowledge of the MAR operon or (d) compounds involving novel genes which affect antibiotic resistance or microbial infectivity and which are
derived from studies of the MAR operon or (e) compounds that affect any such genes. 

 “Field of Use” shall mean the Medical Field of Use and
Disinfectant Field of Use, collectively. 
 (b) The definition of Licensed Products in Section 1.6 of the License
Agreement is hereby amended by adding the following at the end of the definition: 
 “For purposes of clarity, the Parties
hereby agree that [ * ] shall be treated as Licensed Products.” 
 (c) The first sentence of Section 3.3 of the
License Agreement is hereby deleted in its entirety and the following is hereby inserted in lieu thereof: 

“Licensee agrees to pay to Tufts a minimum royalty payment of Twenty Five Thousand Dollars ($25,000) at the end of
each twelve-month period commencing on each anniversary of the Effective Date.” 
 (d) Section 3.4 of the License
Agreement is hereby deleted in its entirety and the following is hereby inserted in lieu thereof: 
 “3.4
Running Royalties. 
 For the Medical Field of Use, Licensee agrees to pay to Tufts royalties of: 

[ * ] percent ([ * ]%) of the Gross Sales of Licensed Products, (a) that are comprised of or contain
Licensed Compounds or (b) the making, using, or selling of which infringes (were it not for the License) at least one claim in an issued, unexpired and non-lapsed patent included in the Patent Rights or would infringe (were it not for the
License) at least one claim in a pending patent application included in the Patent Rights, if such claim were to issue. 
 For
the Disinfectant Field of Use, Licensee agrees to pay to Tufts royalties of: 
 [ * ] percent ([ *
]%) of the Gross Sales of Licensed Products, (a) that are comprised of or contain Licensed Compounds or (b) the making, using, or selling of which infringes (were it not for the License) at least one claim in an issued, unexpired and
non-lapsed patent included in the Patent Rights or would infringe (were it not for the License) at least one claim in a pending patent application included in the Patent Rights, if such claim were to issue.” 

(e) The following new Section 3.6A of the License Agreement is hereby inserted immediately before Section 3.6: 

“3.6A Licensee Challenge. In the event Licensee, its affiliates or subsidiaries, directly or indirectly through a third party,
initiates a Challenge or assists any party in doing so then, commencing on the date that such Challenge is initiated and continuing until such Challenge is irrevocably withdrawn: (a) the [ * ] shall be [ * ] and
(b) Licensee’s right to withhold any royalty identified in Section 3.6 shall not be applicable, in the case of each of (a), (b) and (c) of Section 3.6 until such Challenge has been withdrawn irrevocably. As used herein,
the term “Challenge” shall mean any challenge to the validity or enforceability of any patents or patent applications owned in whole or in part by Tufts by: (a) filing a declaratory judgment action in which any such patents or patent
applications is alleged to be invalid or unenforceable; (b) filing a request for re-examination of 

  
 2 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
any of such patents or patent applications pursuant to 35 U.S.C. §302 and/or §311, or provoking or becoming party to an interference with an application for any such patents or patent
applications pursuant to 35 U.S.C. §135; or (c) filing or commencing any post grant review, inter partes review, third party observation, derivation, opposition, cancellation, nullity or similar proceedings against any of such patents or
patent applications.”  
 (f) The fourth paragraph of Article VI of the License Agreement is hereby deleted in its
entirety and the following is hereby inserted in lieu thereof: 
 “Notwithstanding the foregoing, Tufts shall have the
right at any time after [ * ] to convert the License hereunder to non-exclusive if Licensee, its Subsidiaries or its sublicensees have not by the time of such conversion met each of the following milestones by the applicable date: 

 

			
	 Milestone
	 	 Due By

	[ * ]	 	

 (g) The Novartis Amendment is hereby terminated and of no further force and effect. 

2. Payment of Minimum Royalty Fee. The $25,000 Minimum Royalty Fee for the license period through the Amendment Effective Date
shall be paid by Licensee to Tufts within [ * ] days of the date that Licensee receives an invoice from Tufts on and after the Amendment Effective Date. 
 3. Further Clarification of Terms. Tufts hereby agrees to cooperate with Licensee, including by taking such actions reasonably requested by Licensee, to enforce, commercialize products under,
protect and/or maintain foreign patents or patent applications included as Patent Rights under the License Agreement, as amended by the Amendment, in each case including any divisions, continuations, continuations-in-part, re-examinations,
extensions, renewals, or reissues of such patents or patent applications. Licensee hereby agrees to cooperate with Tufts to properly reflect the rights of Tufts in any patents or patent applications covering any products that include or contain any
compound identified as a lead by Paratek, in each case including any divisions, continuations, continuations-in-part, re-examinations, extensions, renewals, or reissues of such patents or patent applications. Licensee will file and prosecute patent
applications or claims to pending patent applications corresponding to the Patent Rights as reasonably requested by Tufts. Licensee shall reimburse Tufts for its reasonable attorneys’ fees and out-of-pocket costs incurred on and after the
Amendment Effective Date in so doing, up to a maximum amount equal to $[ * ] for the period commencing on the Amendment Effective Date and ending on January 31, 2014 and $[ * ] each twelve (12) month period thereafter, which
shall be payable in arrears within [ * ] days upon submission by Tufts to Licensee of an invoice evidencing such fees and costs.  
 4. Covenant. The Parties hereby covenant and agree to use commercially reasonable efforts to reach a mutually satisfactory agreement on an amendment to Exhibit A to the License Agreement as
soon as practicable after the Amendment Effective Date and before [ * ]. 

  
 3 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 5. Confirmation. Tufts hereby confirms to Licensee that Licensee, as of the date of
the Amendment: (a) has provided to Tufts all annual and any other reports required pursuant to Article VI of the License Agreement; and (b) has made the payments required by Sections 3.1, and 3.3 (including but not limited to Sponsored
Research Agreement payments) under the License Agreement. 
 6. Miscellaneous. The Parties hereby confirm and agree that
the License Agreement, as amended hereby and as further provided in this Amendment, together shall constitute the entire amended License Agreement among the parties, remains in full force and effect and is a binding obligation of the Parties hereto.
This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [Remainder of page intentionally left blank.] 

  
 4 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 IN WITNESS WHEREOF, the Parties hereto have executed this Amendment as of the Amendment
Effective Date. 
  

			
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	/s/ Dennis Molnar
	 Name:
 Title:
	 	 Dennis Molnar
 President and
Chief Executive Officer

  

			
	 TUFTS UNIVERSITY A/K/A TRUSTEES OF
 TUFTS COLLEGE

		
	By:	 	/s/ David R. Harris
	 Name:
 Title:
	 	 David R. Harris

Provost & Senior Vice President

  
 5 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 AMENDMENT NO. 9 TO THE 
 TUFTS UNIVERSITY LICENSE AGREEMENT

 This Amendment No. 9 to the Tufts University License Agreement (this “Amendment”), dated as
of June 24th, 2014 (the “Amendment Effective Date”) is by and between Paratek Pharmaceuticals, Inc. (“Licensee”), and Tufts University, a/k/a Trustees of Tufts College (“Tufts”). Each of
Licensee and Tufts is sometimes referred to individually herein as a “Party” and collectively as the “Parties”. 
 WHEREAS, the Parties entered into the Tufts University License Agreement, effective as of February 1, 1997 and entered into amendments thereto: Amendment No. 1 dated as of
December 29, 1997, Amendment No. 2 dated July 31, 1998, Amendment No. 3 dated June 3, 1999, Amendment No. 4 dated August 14, 2000, Amendment No. 5 dated September 10, 2001, Amendment No. 6 dated
December 11, 2002, Amendment No. 7 dated July 1, 2003 and Amendment No. 8 dated November 20, 2012, as so amended, the “License Agreement”; and 

WHEREAS, the Parties now wish to further amend the License Agreement as set forth herein. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows: 
  

	 	1.	Amendments to Agreement. 

(a) The fourth paragraph of Article VI of the License Agreement is hereby deleted in its entirety and the following is hereby inserted
in lieu thereof: 
 “Notwithstanding the foregoing, Tufts shall have the right at any time after [ * ] to convert the
License hereunder to non-exclusive if Licensee, its Subsidiaries or its sublicensees have not by the time of such conversion met each of the following milestones by the applicable date: 

 

			
	 Milestone
	 	 Due By

	[ * ]	 	

 (b) The Covenant in Section 4 of Amendment No. 8 is hereby deleted in its entirety and the
following is hereby inserted in lieu thereof: 
 “4. Covenant. The Parties hereby covenant and agree to use
commercially reasonable efforts to reach a mutually satisfactory agreement on an amendment to Exhibit A to the License Agreement as soon as practicable after the Amendment Effective Date and before [ * ].” 

 2. Payment of outstanding Minimum Royalty Fees due under Section 2 of Amendment
No. 8. The $25,000 Minimum Royalty Fee described in the invoice dated [ * ] and attached as Appendix A to this Amendment No. 9 shall be paid by Licensee to Tufts by [ * ]. The $25,000 Minimum Royalty Fee described in the
invoice dated [ * ] and attached as Appendix B to this Amendment No. 9 shall be paid by Licensee to Tufts within by [ * ]. 
 3. Miscellaneous. The Parties hereby confirm and agree that the License Agreement, as amended hereby and as further provided in this Amendment, together shall constitute the entire amended License
Agreement among the parties, remains in full force and effect and is a binding obligation of the Parties hereto. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. 
 [Remainder of page intentionally left blank.] 

  
 2 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 IN WITNESS WHEREOF, the Parties hereto have executed this Amendment as of the Amendment
Effective Date. 
  

			
	PARATEK PHARMACEUTICALS, INC.
		
	By:	 	/s/ Dennis Molnar
	 Name:
 Title:
	 	 Dennis Molnar
 President and
Chief Executive Officer

  

			
	 TUFTS UNIVERSITY A/K/A TRUSTEES OF
 TUFTS COLLEGE

		
	By:	 	/s/ Diane L. Souvaine
	 Name:
 Title:
	 	 Diane L. Souvaine

Vice-Provost for Research

  
 3 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 Appendix A 
 TUFTS UNIVERSITY 
 Office for Technology Licensing and Industry Collaboration

 136 Harrison Avenue, Suite 75K-950 
 Boston, MA 02111 
 FEIN 04 210 3634 

[ * ]  
 Tufts invoice
13/OTLIC/083 (revised) 
 By email to dmolnar@Paratekpharm.com 
 Dennis Molnar 
 President, Chief Executive Officer 

Paratek Pharmaceuticals, Inc. 
 75 Kneeland
Street 
 Boston, MA 02111 
  

	Re:	Tufts University—Paratek Pharmaceuticals License Agreement 

 effective February 1, 1997 
 Amendment 8 of November 20, 2012 

Amendment to section 3.3 
 Minimum royalty payment of twenty five thousand dollars at the end of each twelve month period commencing on each anniversary of effective date 
 INVOICE 
 Fee due for license period through the amendment 8 effective date 

February 1, 2012, through January 31,
2013                                         
                       $25,000.00 
 Please make your check payable to Tufts University and send it to 
 Thomas McVarish 

Tufts University 
 Office of the Vice Provost

 Suite 75K-950 
 136 Harrison Avenue

 Boston, MA 02111 
 Phone
• [ * ] E-mail • [ * ] 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 Appendix B 
 TUFTS UNIVERSITY 
 Office for Technology Licensing and Industry Collaboration

 136 Harrison Avenue, Suite 75K-950 
 Boston, MA 02111 
 FEIN 04 210 3634 

[ * ]  
 Tufts invoice
14/OTLIC/062 
 By email to dmolnar@Paratekpharm.com 
 Dennis Molnar 
 President, Chief Executive Officer 

Paratek Pharmaceuticals, Inc. 
 75 Kneeland
Street 
 Boston, MA 02111 
  

	Re:	Tufts University—Paratek Pharmaceuticals License Agreement 

 effective February 1, 1997 
 Amendment 8 of November 20, 2012 

Amendment to section 3.3 
 Minimum royalty payment of twenty five thousand dollars at the end of each twelve month period commencing on each anniversary of effective date 
 INVOICE 
 Fee due for license period 
 February 1, 2013, through January 31,
2014                                         
                   $25,000.00 
 Please make your
check payable to Tufts University and send it to 
 Thomas McVarish 
 Tufts University 
 Office of the Vice Provost 

Suite 75K-950 
 136 Harrison Avenue 

Boston, MA 02111 
 Phone • [ * ]
E-mail • [ * ] 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.EX-10.18

 EXHIBIT 10.18 
  

			
	

		 75 Kneeland Street

Boston, Massachusetts 02111

617 275 0040

617 275 0039 fax
  

www.paratekpharm.com

 February 4, 2015 
 Douglas
Pagán 
 (Hand Delivery) 
 Re: Amended and
Restated Employment Agreement 
 Dear Doug: 
 On behalf of
Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”) I am pleased to offer you continued employment under the terms of this Amended and Restated Employment Agreement (the “Agreement”). In this
Agreement, you and the Company hereby amend, supersede, and restate in its entirety that certain offer letter agreement between the Company and you dated November 19, 2014 (the “Employment Agreement”). 

Employment Position and Duties 
 You will be employed in
the position of Chief Financial Officer (“CFO”). You will be expected to perform the customary duties of your position, duties specified in the Bylaws of the Company, and as may be required by the Company’s Board of Directors
(the “Board”) consistent with your position as CFO. You will report to the Chief Executive Officer, and work at the Company’s corporate headquarters in Boston, Massachusetts. During your employment with the Company, you will
devote your full-time best efforts and business time and attention to the business of the Company. As an exempt salaried employee, you will be expected to be available and working during the Company’s regular business hours, and such additional
time as appropriate to manage your responsibilities. The Company reserves the right to reasonably require you to perform your duties at places other than its corporate headquarters from time to time, and to require reasonable business travel,
including international travel, at the Company’s expense. 
 Your employment relationship with the Company will also be governed by the general
employment policies and practices of the Company, except that if the terms of this Agreement conflict, this Agreement will control. 
 Base Salary

 You will earn a salary at the rate of $25,000 per month ($300,000 annualized), less payroll deductions and withholdings (“Base
Salary”), payable on the Company’s regular payroll schedule. The Base Salary will be reviewed on an annual or more frequent basis by the Board (or any authorized committee thereof), and is subject to change in the discretion of the
Board (or any authorized committee thereof). 
 Signing Bonus 

You are eligible to earn a signing bonus in an amount equal to $65,000, representing the compensation you are forfeiting by joining Paratek, subject to payroll
deductions and withholdings, which will become earned on the earlier of: (a) the date you complete ninety (90) days of service with the Company, or (b) the date your employment by Paratek is terminated by Paratek without Cause or by
you for Good Reason, and will become payable on the first regular Company paydate thereafter. 

 Douglas Pagán 

February 4, 2015 
 Page 2 

 

 Discretionary Performance Bonus 

Starting with calendar year 2015, you will be eligible to earn a discretionary performance bonus of up to thirty percent (30%) of your Base Salary,
subject to applicable payroll deductions and withholdings (“Bonus”), based upon the Board’s assessment of your performance, and the Company’s attainment of written targeted goals as determined by the Board in its sole
discretion. Following the close of each calendar year, the Board will determine in its discretion whether you have earned a Bonus, and the amount of any Bonus. You will be eligible to earn a Bonus for any full calendar year provided that you remain
employed by the Company as of December 31of that year. The Bonus, if earned, will be paid no later than March 15 of the calendar year after the year to which it relates. 

Employee Benefits 
 As a regular employee, you will be
eligible to participate in the Company’s standard employee benefits, pursuant to the terms and conditions of the benefit plans and applicable policies, and for any additional benefits provided to the Company’s executive employees
generally. You will also be eligible to accrue paid vacation in accordance with the terms of the Company’s vacation policy. The Company may change employee benefits from time to time in its discretion. Details about these benefits are provided
in the employee handbook and Summary Plan Descriptions, available for your review. 
 Business Expenses 

The Company will pay or reimburse you for all reasonable business expenses incurred or paid by you in the performance of your duties and responsibilities for
the Company, subject to such reasonable substantiation and documentation as may be required by the Company, and subject to any maximum annual limit and other restrictions on or policies governing such expenses as set by the Company from time to
time. 
 Equity Compensation 
 You have been granted
options (the “Options”), under the Paratek Pharmaceuticals, Inc. 2015 Inducement Plan (the “Inducement Plan”), to purchase 160,000 shares of the Company’s Common Stock, at fair market value as determined by the
Board as of the date of grant. The Options will be governed in full by the terms and conditions of the Inducement Plan and your individual grant agreement; provided, however, subject to your continued service (as defined in the Inducement Plan), the
Options will vest over a four (4)-year vesting period, under which twenty-five percent (25%) of your shares will vest after twelve (12) months of employment, with the remaining shares vesting monthly thereafter over the remaining
thirty-six (36)-month period. 
 You have been granted Restricted Stock Units (“RSUs”) under the Transcept Pharmaceuticals, Inc. 2006
Incentive Award Plan, as amended and restated (the “2006 Plan”), for 35,000 shares of Common Stock of the Company. The RSUs will be governed in full by the terms and conditions of the 2006 Plan and your individual Restricted Stock
Unit Award Grant Notice and Restricted Stock Unit Award Agreement; provided, however, subject to your continued service with the Company as defined in the 2006 Plan, the RSUs shall vest and shares of Common Stock shall be issuable upon the three
(3)-year anniversary of the grant date. 

 Douglas Pagán 

February 4, 2015 
 Page 3 

 

 At-Will Employment Relationship 

You may terminate your employment with the Company at any time, with or without Good Reason, and with or without advance notice, and for any reason whatsoever
simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without Cause, and with or without advance notice. Your employment at-will status can only be modified in a written agreement approved by the
Board and signed by you and a duly authorized Member of the Board. 
 Payments upon Termination Other than Without Cause or with Good Reason 

Upon termination of your employment for any reason other than by the Company without Cause or by you with Good Reason, you shall be paid all accrued but unpaid
Base Salary, any earned but unpaid bonus, reimbursement for business expenses incurred by you but not yet paid to you as of the date your employment terminates, and all accrued but unused vacation (collectively, the “Accrued
Payments”). Your Options shall terminate, as to all unvested shares, as of your termination date. 
 Termination without Cause or with Good
Reason 
 Upon termination of your employment at any time by the Company without Cause or by you with Good Reason, each as defined below, you will
receive the Accrued Payments. In addition, subject to your fulfillment of the Release Obligation, as defined below, you will be eligible for the following severance benefits: 

1. Cash Severance Payments. You will be eligible to receive cash severance equal to twelve (12) months of Base Salary following the
termination date, subject to payroll withholding and deduction (“Severance Payments”), and paid according to the Company’s regular payroll procedures. Payment of Severance Payments shall commence on the sixtieth (60th) day following your employment termination, which initial payment shall include a lump sum payment equal to the aggregate semi-monthly installments that would otherwise have been due during the
period between the termination date and the sixtieth (60th) day, but for the sixty (60)-day delay in this provision. Thereafter, the remaining installments shall be paid on the Company’s
regular paydays. 
 2. Pro-Rata Severance Bonus. You will also be eligible to receive an amount (the “Pro-Rata
Bonus”) equal to the Bonus you would have earned for the year in which your employment terminates, prorated by multiplying the Bonus that you would have earned if you had remained employed through December 31 by the portion of the year
that you had actually remained employed, and subject to payroll withholding and deduction. The determination by the Board of the Bonus amount you would have earned shall be based on actual performance for the full calendar year, except that any
applicable subjective performance conditions will be disregarded in determining actual performance, and the entire amount of the Bonus, if any, will be determined based on applicable objective performance conditions. Any Pro-Rata Bonus will be paid
at the same time bonuses are paid to the other executives of the Company, but in no event later than March 15 of the calendar year after the year to which it relates. 

3. Paid Health Care Coverage; Other Benefits Continuation. 

a. If at the time of your employment termination you participate in health care coverage through the Company’s plan, then provided
that you timely elect continued 

 Douglas Pagán 

February 4, 2015 
 Page 4 

 

 
coverage under COBRA, the Company will pay your COBRA premiums to continue your coverage (including coverage for eligible dependents, if applicable) (“COBRA Premiums”) through
the period (the “COBRA Premium Period”) starting on the termination date and ending on the earliest to occur of the date: (i) twelve (12) months after the termination date; (ii) you become eligible for group health
insurance coverage through a new employer; or (iii) you cease to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event you become covered under another employer’s group health plan or
otherwise cease to be eligible for COBRA during the COBRA Premium Period, you must immediately notify the Company of such event. 
 b.
Notwithstanding the foregoing, if the payment by the Company of the COBRA Premiums will subject or expose the Company to taxes or penalties, you and the Company agree to renegotiate the provisions of paragraph 3(a) in good faith and enter into a
substitute arrangement pursuant to which the Company will not be subjected or exposed to taxes or penalties and you will be provided with payments or benefits with an economic value that is no less than the economic value of the COBRA Premiums. 

Definitions 
 For purposes of this Agreement, the
following definitions shall apply: 
 1. “Cause” shall mean the occurrence of any of the following events:
(a) your conviction of any felony or any crime involving fraud, embezzlement, dishonesty or moral turpitude under the laws of the United States or any state thereof; (b) your attempted commission of, or participation in, a fraud,
embezzlement or act of material dishonesty against the Company or a Company affiliate; (c) your intentional, material violation of any contract or agreement between you and the Company or a Company affiliate or of any statutory duty owed to the
Company or a Company affiliate; (d) your intentional unauthorized use or disclosure of the Company’s or a Company affiliate’s confidential information or trade secrets; (e) your refusal or failure to perform any duties required
of you, if such duties are consistent with duties customary for your position, which refusal or failure continues after a period of thirty (30) days following your receipt of notice from the Company that it deems such conduct Cause for
termination of your employment hereunder; or (f) your gross misconduct. 
 Notwithstanding anything to the contrary in this Agreement or
any other Agreement between the Company and you, “Cause” shall not include or be predicated upon any act or omission by you, which is taken or made either (a) in good faith, under your reasonable belief that the act or omission was in
the best interests of the Company; (b) to comply with a lawful court order, directive from a federal, state or local government agency or industry regulatory authority, or subpoena; or (c) at the direction of the Board or upon the advice
of counsel for the Company. 
 2. “Good Reason” shall exist for resignation from employment with the Company if any of the
following actions are taken by the Company without your prior consent: (a) a reduction in your Base Salary or Bonus target percentage of Base Salary, unless the salaries or bonus target percentages of all other senior executive officers of the
Company are correspondingly and proportionately reduced; (b) a removal from the office of CFO; or (c) a relocation of your principal place of employment to a place that increases your one-way

 Douglas Pagán 

February 4, 2015 
 Page 5 

 

 
commute by more than thirty-five (35) miles as compared to your then-current principal place of employment immediately prior to such relocation. In order for you to resign for Good Reason,
each of the following requirements must be met: (w) you must provide written notice to the Board within thirty (30) days after first becoming aware of the first occurrence of the event giving rise to Good Reason setting forth the basis for
your resignation, (x) you must allow the Company at least thirty (30) days from receipt of such written notice (the “Cure Period”) to cure such event, (y) such event is not reasonably cured by the Company within the
Cure Period, and (z) you must resign from all positions you then hold with the Company not later than sixty (60) days after the expiration of the Cure Period. 

3. “Release Obligation” means that: (a) you have signed a general release and waiver of claims in favor of the Company
and its affiliates, as part of a termination agreement acceptable to the Company that contains standard provisions including (i) a mutual non-disparagement provision, (ii) a provision providing that, notwithstanding anything to the
contrary in any agreement between you and the Company, each party will be responsible for its own expenses incurred in connection with the enforcement of such agreement, and (iii) customary exclusions from your release of claims including
(A) any claims with respect to amounts due and owing to you pursuant to the terms and conditions of this Agreement or under any other employee benefit plan of the Company or its affiliates; (B) any claims or rights you may have to
indemnification or advancement of expenses under the by-laws or other applicable corporate governing documents of the Company or any other plan, policy, agreement, or arrangement, or under applicable law; (C) any rights, coverage or
entitlements provided to you under any D&O insurance policies paid for by the Company (or its affiliates); and (D) any rights or claims you may have against the Company or its affiliates which arise after the date of the termination
agreement, and (b) you have allowed the release and waiver to become fully effective without revocation during any applicable revocation period. 

Change in Control 
 Upon the termination of your
employment by the Company without Cause, or by you with Good Reason, in either case during a time period starting on the date ninety (90) days before the closing of a Change in Control and ending on the date twelve (12) months after the
closing of a Change in Control, provided that you meet the Release Obligation and you provide continued services through your termination date, then your Options and RSUs shall vest in full (“Accelerated Vesting”), effective as of
the termination date of your employment. 
 A “Change in Control” shall mean any of the following: (a) a merger or consolidation in
which the Company is a constituent party (or if a subsidiary of the Company is a constituent party and the Company issues shares of its capital stock pursuant to such merger or consolidation), other than a merger or consolidation in which the voting
securities of the Company outstanding immediately prior to such merger or consolidation continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent
(50%) of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation, or (b) any transaction or series of related transactions in which in excess of fifty percent
(50%) of the Company’s voting power is transferred, other than the sale by the Company of stock in transactions the primary purpose of which is to raise capital for the Company’s operations and activities, or (c) a sale, lease,
exclusive license or other disposition of all or substantially all (as determined by the Board in its sole discretion) of the assets of the Company. 

 Douglas Pagán 

February 4, 2015 
 Page 6 

 

 Section 280G 

If any payment or benefit (including payments and benefits pursuant to this Agreement) that you would receive in connection with a Change in Control from the
Company or otherwise (“Transaction Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Internal Revenue Code (the “Code”), and (ii) but for this
sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Company shall cause to be determined, before any amounts of the Transaction Payment are paid to you, which of the following
two alternative forms of payment would result in your receipt, on an after-tax basis, of the greater amount of the Transaction Payment notwithstanding that all or some portion of the Transaction Payment may be subject to the Excise Tax:
(1) payment in full of the entire amount of the Transaction Payment (a “Full Payment”), or (2) payment of only a part of the Transaction Payment so that you receive the largest payment possible without the imposition of
the Excise Tax (a “Reduced Payment”). For purposes of determining whether to make a Full Payment or a Reduced Payment, the Company shall cause to be taken into account all applicable federal, state and local income and
employment taxes and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes). If a Reduced Payment is
made, (x) you shall have no rights to any additional payments and/or benefits constituting the Transaction Payment, and (y) reduction in payments and/or benefits shall occur in the manner that results in the greatest economic benefit to
you as determined in this paragraph. If more than one method of reduction will result in the same economic benefit, the portions of the Transaction Payment shall be reduced pro rata. Unless you and the Company otherwise agree in writing,
any determination required under this paragraph shall be made in writing by the Company’s independent public accountants (the “Accountants”), whose determination shall be conclusive and binding upon you and the Company for all
purposes. For purposes of making the calculations required by this paragraph, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the
application of Sections 280G and 4999 of the Code. You and the Company shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this paragraph. The
Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this paragraph as well as any costs incurred by you with the Accountants for tax planning under Sections 280G and 4999 of the Code.

 Indemnification; D&O Insurance 
 You will be
entitled to the same indemnification under the terms of the Company’s by-laws and Certificate of Incorporation as is provided, and such liability insurance as the Company may from time to time purchase, for its Board members and senior
officers, including such post-termination indemnification and liability insurance as applicable to other Board members and senior executives. As required by the Company’s Certificate of Incorporation, the Company shall enter into its customary
indemnification agreement with you. 
 Compliance with Proprietary Information Agreement and Company Policies 

As a condition of employment, you have signed and must continue to comply with the Company’s standard form of Employee Proprietary Information, Inventions
Assignment, Non-Competition and Non-Solicitation Agreement (the “Proprietary Information Agreement”, a copy of which is attached hereto as Exhibit A) which prohibits unauthorized use or disclosure of the Company’s
proprietary information, among other obligations. As a Paratek employee, you will be expected to abide by Company policies and practices, as may be changed from time to time in the Company’s discretion, and acknowledge in writing that you have
read the Company’s employee handbook. 

 Douglas Pagán 

February 4, 2015 
 Page 7 

 

 Protection of Third Party Information 

In your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any former employer or
other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in
the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises, or use in the performance of your duties, any unpublished documents or
property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the
Company. 
 Outside Activities 
 Except with the prior
written consent of the Board, you will not during your employment engage in any other employment, occupation or business enterprise, other than ones in which you are a passive investor. You may engage in civic and not-for-profit activities so long
as such activities do not materially interfere with the performance of your duties. During your employment, you agree not to acquire, assume or participate in, directly or indirectly, any entity, investment, or interest known by you to be adverse or
antagonistic to the Company, its business or prospects, financial or otherwise, including any person, corporation, firm, partnership or other entity whatsoever known by you to compete with the Company (or is planning or preparing to compete with the
Company), anywhere in the world, in any line of business engaged in (or planned to be engaged in) by the Company. You may purchase or otherwise acquire up to one percent (1%) of any class of securities of any enterprise if such securities are
listed on any national or regional securities exchange, provided that you refrain from participating in the business activities of such enterprise. 

Agreement to Arbitrate 
 To ensure the rapid and
economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company both agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory
claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment with the Company, will be resolved pursuant to the Federal
Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted in Boston, Massachusetts by JAMS, Inc. (“JAMS”) or its successors. 

Both you and the Company acknowledge that by agreeing to this arbitration procedure, you each waive the right to resolve any such dispute through a trial
by jury or judge or administrative proceeding. 
 Any such arbitration proceeding will be governed by JAMS’ then applicable rules and procedures
for employment disputes, which can be found at http://www. jamsadr.com/rules-clauses/, and which will be provided to you upon request. In any such proceeding, the arbitrator shall: (i) have the authority to compel adequate discovery for the
resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii) issue a written arbitration decision including the arbitrator’s essential 

 Douglas Pagán 

February 4, 2015 
 Page 8 

 

 
findings and conclusions and a statement of the award. You and the Company each shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law. Nothing in
this Agreement is intended to prevent either the Company or you from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law. 

Section 409A 
 It is the intention of the parties
that this Agreement comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and applicable guidance issued thereunder (“Section 409A”), and this Agreement will be interpreted in a manner
intended to comply with Section 409A. All payments under this Agreement are intended to be excluded from the requirements of Section 409A or be payable on a fixed date or schedule in accordance with Section 409A(a)(2)(iv).
Notwithstanding anything in this Agreement to the contrary, in the event that you are deemed to be a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) and are not “disabled” within the meaning of
Section 409A(a)(2)(C), no payments hereunder that are “deferred compensation” subject to Section 409A shall be made to you prior to the date that is six (6) months after the date of your “separation from service”
(as defined in Section 409A and any Treasury Regulations promulgated thereunder) or, if earlier, your date of death. Following any applicable six (6) month delay, all such delayed payments will be paid in a single lump sum on the earliest
permissible payment date, together with simple interest on the amount of each delayed payment at the U.S. short term applicable federal rate as of the date of the separation from service. For purposes of this Agreement, with respect to payments of
any amounts that are considered to be “deferred compensation” subject to Section 409A, references to “termination of employment” (and substantially similar phrases) shall be interpreted and applied in a manner that is
consistent with the requirements of Section 409A. For purposes of Section 409A, your right to receive any installment payment pursuant to this Agreement will be treated as a right to receive a series of separate and distinct payments. 

Entire Agreement; Contingencies 
 This Agreement, together
with your Proprietary Information Agreement, forms the complete and exclusive statement of your employment agreement with the Company. It supersedes any other prior agreements or promises made to you by anyone, whether oral or written, including the
Employment Agreement. Changes in your employment terms, other than those changes expressly reserved to the Company’s or Board’s discretion in this Agreement, require a written modification approved by the Board and signed by a duly
authorized Member of the Board. 
 This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and
inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of
this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. 

This Agreement shall be construed and enforced in accordance with the laws of the Commonwealth of Massachusetts without regard to conflicts of law principles.
Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder. This Agreement may be executed in counterparts which shall be deemed to be part
of one original, and pdf or other facsimile signatures shall be equivalent to original signatures. 

 Douglas Pagán 

February 4, 2015 
 Page 9 

 

 Please sign and date this Agreement to indicate your acceptance of continued employment at Paratek under the
terms described above. We look forward to a continued productive and enjoyable work relationship. 
 Sincerely, 

Paratek Pharmaceuticals, Inc. 
  

	
	 /s/ MICHAEL F. BIGHAM

	 Michael F. Bigham

	 Chairman of the Board and Chief Executive Officer

  

	
	Accepted:
	
	 /s/ DOUGLAS PAGAN

	 Douglas Pagán

 

			
		
	 Date: 
		 February 25, 2015

 Exhibit A 

EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS ASSIGNMENT, NON- 

COMPETITION 
 AND
NON-SOLICITATION AGREEMENT 

 Exhibit A 

EMPLOYEE PROPRIETARY INFORMATION, INVENTIONS ASSIGNMENT, NON-COMPETITION 

AND NON-SOLICITATION AGREEMENT 

In consideration of my employment or continued employment by Paratek Pharmaceuticals, Inc., its subsidiaries, parents, affiliates,
successors and assigns (together, the “Company”) and the compensation now and hereafter paid to me, I hereby enter into this Employee Proprietary Information, Inventions Assignment, Non-Competition and Non-Solicitation Agreement
(the “Agreement”) and agree as follows: 

 

 1. NONDISCLOSURE. 

1.1 Recognition of Company’s Rights; Nondisclosure. I understand and acknowledge that my employment by the Company creates a
relationship of confidence and trust with respect to the Company’s Proprietary Information (defined below) and that the Company has a protectable interest therein. At all times during my employment and thereafter, I will hold in strictest
confidence and will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information, except as such disclosure, use or publication may be required in connection with my work for the Company, or unless an authorized
officer of the Company expressly authorizes such in writing. I will obtain the Company’s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that relates to my work at the Company and/or
incorporates any Proprietary Information. I hereby assign to the Company any rights I may have or acquire in such Proprietary Information and recognize that all Proprietary Information shall be the sole property of the Company and its assigns. I
will take all reasonable precautions to prevent the inadvertent or accidental disclosure of Proprietary Information. 
 1.2 Proprietary
Information. The term “Proprietary Information” shall mean any and all confidential and/or proprietary knowledge, data or information of the Company, its affiliates, parents and subsidiaries, whether having existed, now
existing, or to be developed during my employment. By way of illustration but not limitation, “Proprietary Information” includes (a) trade secrets, inventions, ideas, processes, formulas, assay components, biological materials,
cell lines, and clinical data, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Proprietary Rights therein (hereinafter collectively
referred to as “Inventions”); (b) information regarding research, development, new products, marketing and selling, business

 
plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining business,
forecasts, future plans and potential strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities and agreements, internal services and operational manuals, methods of conducting
Company business, suppliers and supplier information, and purchasing; (c) information regarding customers and potential customers of the Company, including customer lists, names, representatives, their needs or desires with respect to the types
of products or services offered by the Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of the Company and other
non-public information relating to customers and potential customers; (d) information regarding any of the Company’s business partners and their services, including names; representatives, proposals, bids, contracts and their contents and
parties, the type and quantity of products and services received by the Company, and other non-public information relating to business partners; (e) information regarding personnel, employee lists, compensation, and employee skills; and
(f) any other non-public information which a competitor of the Company could use to the competitive disadvantage of the Company. Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which is
generally known in the trade or industry through no breach of this Agreement or other act or omission by me, and I am free to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the
National Labor Relations Act. 
 1.3 Third Party Information. I understand, in addition, that the Company has received and in the
future will receive confidential and/or proprietary knowledge, data, or information from third parties (“Third Party Information”).

 

 
During my employment and thereafter, I will hold Third Party Information in the strictest confidence and will not disclose to anyone (other than Company personnel who need to know such
information in connection with their work for the Company) or use, except in connection with my work for the Company, Third Party Information unless expressly authorized by an authorized officer of the Company in writing. 

1.4 Term of Nondisclosure Restrictions. I understand that Proprietary Information and Third Party Information is never to be used or
disclosed by me, as provided in this Section 1. If, however, a court decides that this Section 1 or any of its provisions is unenforceable for lack of reasonable temporal limitation and the Agreement or its restriction(s) cannot otherwise
be enforced, I agree and the Company agrees that the two (2) year period after the date my employment ends shall be the temporal limitation relevant to the contested restriction, provided, however, that this sentence shall not apply to trade
secrets protected without temporal limitation under applicable law. 
 1.5 No Improper Use of Information of Prior Employers and
Others. During my employment by the Company I will not improperly use or disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not
bring onto the premises of the Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.

 2. ASSIGNMENT OF INVENTIONS. 

2.1 Proprietary Rights. The term “Proprietary Rights” shall mean all trade secrets, patents, copyrights, trade marks
and other intellectual property rights throughout the world. 
 2.2 Prior Inventions. Inventions, if any, patented or unpatented,
which I made prior to the commencement of my employment with the Company are excluded from the scope of this Agreement. To preclude any possible uncertainty, I have set forth on Exhibit 1 (Prior Inventions) attached hereto a complete
list of all Inventions that I have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of my employment with the Company, that I

 
consider to be my property or the property of third parties, and that I wish to have excluded from the scope of this Agreement (collectively referred to as “Prior Inventions”).
If disclosure of any such Prior Invention would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Prior Inventions in Exhibit 1 but am only to disclose a cursory name for each such
invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason. A space is provided on Exhibit 1 for such purpose. If no such disclosure is attached, I
represent that there are no Prior Inventions. If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product, process or machine, the Company is hereby granted and shall have a nonexclusive, royalty-free,
irrevocable, perpetual, fully-paid, worldwide license (with rights to sublicense through multiple tiers of sublicensees) to make, have made, modify, make derivative works of, publicly perform, use, sell, import, and exercise any and all present and
future rights in such Prior Invention. Notwithstanding the foregoing, I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions without the Company’s prior written consent. 

2.3 Assignment of Inventions. Subject to Subsection 2.4, I hereby assign, grant and convey to the Company all my right, title and
interest in and to any and all Inventions (and all Proprietary Rights with respect thereto) whether or not patentable or registrable under copyright or similar statutes, made or conceived or reduced to practice or learned by me, either alone or
jointly with others, during the period of my employment with the Company. Inventions assigned to the Company or its designee are hereinafter referred to as “Company Inventions.” 

2.4 Unassigned or Nonassignable Inventions. I recognize that this Agreement will not be deemed to require assignment of any Invention
that I developed entirely on my own time without using the Company’s equipment, supplies, facilities, trade secrets, or Proprietary Information, except for those Inventions that either (i) relate to the Company’s actual or anticipated
business, research or development, or (ii) result from or are connected with work performed by me for the Company. In addition, this Agreement does not apply to any Invention which qualifies fully for protection from assignment to the Company
under any specifically applicable state law, regulation, rule, or public policy (“Specific Inventions Law”). 

 

  
 A-2 

 2.5 Obligation to Keep Company Informed. During the period of my employment and for six
(6) months after termination of my employment with the Company, I will promptly disclose to the Company fully and in writing all Inventions authored, conceived or reduced to practice by me, either alone or jointly with others. In addition, I
will promptly disclose to the Company all patent applications filed by me or on my behalf within a year after termination of employment. At the time of each such disclosure, I will advise the Company in writing of any Inventions that I believe fully
qualify for protection under the provisions of a Specific Inventions Law; and I will at that time provide to the Company in writing all evidence necessary to substantiate that belief. The Company will keep in confidence and will not use for any
purpose or disclose to third parties without my consent any confidential information disclosed in writing to the Company pursuant to this Agreement relating to Inventions that qualify fully for protection under a Specific Inventions Law. I will
preserve the confidentiality of any Invention that does not fully qualify for protection under a Specific Inventions Law. 
 2.6
Ownership of Work Product. I agree that the Company will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment, and I hereby irrevocably and unconditionally assign to the Company
all right, title, and interest worldwide in and to such work product. I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by copyright
are “works made for hire,” pursuant to United States Copyright Act (17 U.S.C., Section 101). I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any work product protected by
this Section, except as necessary to perform services for the Company. 
 2.7 Enforcement of Proprietary Rights. I will assist the
Company in every proper way to obtain, and from time to time enforce, United States and foreign Proprietary Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform
such other acts (including appearances as a witness) as the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Proprietary Rights and the assignment thereof. In addition, I will
execute, verify and deliver assignments of such Proprietary Rights to the Company or its designee, including the United

 
States or any third party designated by the Company. My obligation to assist the Company with respect to Proprietary Rights relating to such Company Inventions in any and all countries shall
continue beyond the termination of my employment, but the Company shall compensate me at a reasonable rate after my termination for the time actually spent by me at the Company’s request on such assistance. 

In the event the Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with
the actions specified in the preceding paragraph, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in
my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me. I hereby waive and quitclaim to the
Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Proprietary Rights assigned under this Agreement to the Company. 

3. RECORDS. I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in
any other form that may be required by the Company) of all Proprietary Information developed by me and all Inventions made by me during the period of my employment at the Company, which records shall be available to and remain the sole property of
the Company at all times. 
 4. DUTY OF LOYALTY DURING
EMPLOYMENT. I agree that during the period of my employment by the Company I will not, without the Company’s express written consent, directly or indirectly engage in any employment or business activity which is directly or
indirectly competitive with, or would otherwise conflict with, my employment by the Company. 
 5. NO
SOLICITATION OF EMPLOYEES, CONSULTANTS, CONTRACTORS, OR CUSTOMERS OR POTENTIAL CUSTOMERS. I
agree that during the period of my employment and for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by the Company, I will not, as
an officer, director, employee, consultant, owner, partner, or in any other 

 

  
 A-3 

 
capacity, either directly or through others, except on behalf of the Company: 

5.1 solicit, induce, encourage, or participate in soliciting, inducing, or encouraging any employee of the Company to terminate his
or her relationship with the Company; 
 5.2 hire, employ, or engage in business with or attempt to hire, employ, or engage in
business with any person employed by the Company or who has left the employment of the Company within the preceding three (3) months of any such prohibited activity or discuss any potential employment or business association with such person,
even if I did not initiate the discussion or seek out the contact; 
 5.3 solicit, induce or attempt to induce any Customer or
Potential Customer, or any consultant or independent contractor with whom I had direct or indirect contact during my employment with the Company or whose identity I learned as a result of my employment with the Company, to terminate, diminish, or
materially alter in a manner harmful to the Company its relationship with the Company; or 
 5.4 solicit, perform, provide or
attempt to perform or provide any Conflicting Services (as defined in Section 6 below) for a Customer or Potential Customer. 
 The parties agree that
for purposes of this Agreement, a “Customer or Potential Customer” is any person or entity who or which, at any time during the one (1) year prior to the date my employment with the Company ends, (i) contracted for,
was billed for, or received from the Company any product, service or process with which I worked directly or indirectly during my employment by the Company or about which I acquired Proprietary Information; or (ii) was in contact with me or in
contact with any other employee, owner, or agent of the Company, of which contact I was or should have been aware, concerning any product, service or process with which I worked directly or indirectly during my employment with the Company or about
which I acquired Proprietary Information; or (iii) was solicited by the Company in an effort in which I was involved or of which I was or should have been aware. 

6. NON-COMPETE PROVISION. I agree that for the one (1) year period after the date my employment ends
for any reason, including but not limited to voluntary termination by me or involuntary termination by the Company, I will not, directly or indirectly, as an officer, director, employee, consultant, owner,

 
manager, member, partner, or in any other capacity solicit, perform, or provide, or attempt to perform or provide Conflicting Services anywhere in the world where the Company conducts business,
including but not limited to locations where the Company performs research or development activities related to the Company’s products, services or processes (such locations the “Restricted Territory”), nor will I assist
another person to solicit, perform or provide or attempt to perform or provide Conflicting Services in the Restricted Territory. 
 The parties agree that
for purposes of this Agreement, “Conflicting Services” means any product, service, or process or the research and development thereof, of any person or organization other than the Company that has antibiotics as its principal
business, unless otherwise expressly excluded from this definition in advance by the Company’s Board of Directors. 
 7. REASONABLENESS OF
RESTRICTIONS. 
 7.1 I agree that I have read this entire Agreement and understand it. I agree that this Agreement does not
prevent me from earning a living or pursuing my career and that I have the ability to secure other non-competitive employment using my marketable skills. I agree that the restrictions contained in this Agreement are reasonable, proper, and
necessitated by the Company’s legitimate business interests, including without limitation, the Company’s Proprietary Rights, Proprietary Information and the goodwill of its customers. I represent and agree that I am entering into this
Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it. 

7.2 In the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, the
Company and I agree that the court shall read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum extent allowed by law. 

7.3 If the court declines to enforce this Agreement in the manner provided in subsection 7.2, I and the Company agree that this
Agreement will be automatically modified to provide the Company with the maximum protection of its business interests allowed by law and I agree to be bound by this Agreement as modified.

 

  
 A-4 

 8. NO CONFLICTING AGREEMENT OR
OBLIGATION. I represent that my performance of all the terms of this Agreement and as an employee of the Company does not and will not breach any agreement or obligation of any kind to keep in confidence information acquired by me
in confidence or in trust prior to my employment by the Company. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement. 

9. RETURN OF COMPANY PROPERTY. Upon termination of my employment or upon Company’s
request at any other time, I will deliver to Company all of Company’s property, equipment, and documents, together with all copies thereof, and any other material containing or disclosing any Inventions, Third Party Information or Proprietary
Information and certify in writing that I have fully complied with the foregoing obligation. I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company. In
addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Proprietary Information, I agree to provide the Company with a
computer-useable copy of all such Proprietary Information and then permanently delete and expunge such Proprietary Information from those systems; and I agree to provide the Company access to my system as reasonably requested to verify that the
necessary copying and/or deletion is completed. I further agree that any property situated on Company’s premises and owned by Company is subject to inspection by Company’s personnel at any time with or without notice. Prior to the
termination of my employment or promptly after termination of my employment, I will cooperate with Company in attending an exit interview and certify in writing that I have complied with the requirements of this section. 

10. LEGAL AND EQUITABLE REMEDIES. 

10.1 I agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree
that any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to the Company and the Company shall have the right to enforce this Agreement and any of its provisions by injunction,
specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach or threatened breach of this Agreement.

 10.2 I agree that if the Company is successful in whole or in part in any legal or
equitable action against me under this Agreement, the Company shall be entitled to payment of all costs, including reasonable attorney’s fees, from me. 

10.3 In the event the Company enforces this Agreement through a court order, I agree that the restrictions of Sections 5 and 6 shall
remain in effect for a period of twelve (12) months from the effective date of the Order enforcing the Agreement. 
 11. NOTICES.
Any notices required or permitted under this Agreement will be given to the Company at its headquarters location at the time notice is given, labeled “Attention Chief Executive Officer,” and to me at my address as listed on the Company
payroll, or at such other address as the Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If delivered by certified or registered mail, notice will be considered to have been
given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service
receipt. 
 12. PUBLICATION OF THIS AGREEMENT TO SUBSEQUENT EMPLOYERS OR BUSINESS ASSOCIATES OF EMPLOYEE. 

12.1 If I am offered employment or the opportunity to enter into any business venture as owner, partner, consultant or other capacity
while the restrictions described in Sections 5 and 6 of this Agreement are in effect I agree to inform my potential employer, partner, co-owner and/or others involved in managing the business with which I have an opportunity to be associated of my
obligations under this Agreement and also agree to provide such person or persons with a copy of this Agreement. 
 12.2 I agree to
inform the Company of all employment and business ventures which I enter into while the restrictions described in Sections 5 and 6 of this Agreement are in effect and I also authorize the Company to provide copies of this Agreement to my employer,
partner, co-owner and/or others involved in managing the business with which I am employed or associated and to make such persons aware of my obligations under this Agreement.

 

  
 A-5 

 13. GENERAL PROVISIONS. 

13.1 Governing Law; Consent to Personal Jurisdiction. This Agreement will be governed by and construed according to the laws of the
Commonwealth of Massachusetts as such laws are applied to agreements entered into and to be performed entirely within the Commonwealth of Massachusetts between Massachusetts residents. I hereby expressly consent to the personal jurisdiction and
venue of the state and federal courts located in the Commonwealth of Massachusetts for any lawsuit filed there against me by Company arising from or related to this Agreement. 

13.2 Severability. In case any one or more of the provisions, subsections, or sentences contained in this Agreement shall, for any
reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or
unenforceable provision had never been contained in this Agreement. If moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or
subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear. 

13.3 Successors and Assigns. This Agreement is for my benefit and the benefit of the Company, its successors, assigns, parent
corporations, subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives. 

13.4 Survival. The provisions of this Agreement shall survive the termination of my employment, regardless of the reason, and the
assignment of this Agreement by the Company to any successor in interest or other assignee. I understand that my obligations under this Agreement will continue in accordance with its express terms regardless of any change in my title, position,
status, role, duties, salary, compensation or benefits or other terms and conditions of employment or service.

 13.5 Employment At-Will. I agree and understand that nothing in this Agreement shall
change my at-will employment status or confer any right with respect to continuation of employment by the Company, nor shall it interfere in any way with my right or the Company’s right to terminate my employment at any time, with or without
cause or advance notice. 
 13.6 Waiver. No waiver by the Company of any breach of this Agreement shall be a waiver of any
preceding or succeeding breach. No waiver by the Company of any right under this Agreement shall be construed as a waiver of any other right. The Company shall not be required to give notice to enforce strict adherence to all terms of this
Agreement. 
 13.7 Advice of Counsel. I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF
INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT. 

13.8 Entire Agreement. The obligations pursuant to Sections 1 and 2 (except Subsection 2.6) of this Agreement shall apply to any time
during which I was previously engaged, or am in the future engaged, by the Company as a consultant if no other agreement governs nondisclosure and assignment of inventions during such period. This Agreement is the final, complete and exclusive
agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be
effective unless in writing and signed by the party to be charged. Any subsequent change or changes in my title, position, status, role, duties, salary, compensation or benefits or other terms and conditions of employment or service will not affect
the validity or scope of this Agreement. 

 

  
 A-6 

 This Agreement shall be effective as of the first day of my employment with the Company. 

 

 DOUGLAS PAGAN: 

I HAVE READ, UNDERSTAND, AND ACCEPT THIS AGREEMENT
AND HAVE BEEN GIVEN THE OPPORTUNITY TO REVIEW IT WITH INDEPENDENT
LEGAL COUNSEL. 

 PARATEK PHARMACEUTICALS, INC. 

ACCEPTED AND AGREED:

 

  

			
	 /s/ DOUGLAS PAGAN
		 /s/ MICHAEL F. BIGHAM

	(Signature)		(Signature)

							
				
	Date:		 December 1, 2014
		By:		 Michael F. Bigham

			
	 Address: 48 Winthrop Street, Winchester, MA 01890
		Title:		 Chairman and CEO

				
					Date:		 November 20, 2014

			
					Address: 75 Kneeland Street, Boston, Massachusetts 02111

  
 A-7 

 EXHIBIT 1 

PRIOR INVENTIONS 
  

			
	TO:		Paratek Pharmaceuticals, Inc.
		
	FROM:		Douglas Pagan
		
	DATE:		December 1, 2014                        
		
	SUBJECT:		Prior Inventions

 1. Except as listed in Section 2 below, the following is a complete list of all inventions or improvements
relevant to the subject matter of my employment by Paratek Pharmaceuticals, Inc. (the “Company”) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the
Company: 
  

					
			x    		No inventions or improvements.
			
			 ̈    		See below:
			
					  

			
					  

			
					  

  

	 ̈	Additional sheets attached. 

 2. Due to a prior confidentiality agreement, I cannot complete the
disclosure under Section 1 above with respect to inventions or improvements generally listed below, the proprietary rights and duty of confidentiality with respect to which I owe to the following party(ies): 

 

											
			Invention or Improvement				Party(ies)				Relationship
						
	1.		  
				  
				  

						
	2.		  
				  
				  

						
	3.		  
				  
				  

						
	 ̈		Additional sheets attached.								

  
 A-8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]